[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 105
1. Kastritis E, Dimopoulos MA, Antoniou N, Deliveliotis C, Chrisofos M, Skolarikos A, Gika D, Bamias A: The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res; 2006 Sep-Oct;26(5B):3865-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy.
  • BACKGROUND: There is limited information about the benefit from systemic chemotherapy in non-pure Transitional Cell Carcinomas (TCCs) of the urothelial tract.
  • In this study the efficacy of platinum-based chemotherapy in patients with pure squamous or mixed carcinomas was retrospectively analysed and compared with that in pure TCCs.
  • PATIENTS AND METHODS: Analysis included 446 consecutive patients treated with platinum-based chemotherapy for advanced or metastatic urothelial cancer.
  • There were 389 (87%) patients with pure TCC, 15 (3.5%) with pure Squamous Cell Carcinomas (SCC) and 42 (9.5%) patients had mixed histology (TCC+SCC) tumors.
  • RESULTS: There were no statistically significant differences in baseline characteristics (gender, PS, haemoglobin, sites of metastases) although disease in the pelvis was more frequent in mixed tumors than in pure TCCs (46% vs. 30%, p = 0.034).
  • Median survival for patients with TCC histology was 11.3 months, for SCC patients 13.6 months and 10.4 months for patients with mixed histology (p = 0.720).
  • Response rates were 44% for patients with TCC, 27% for patients with SCC and 34% for mixed histology patients (p = 0.210).
  • Multivariate analysis showed that presence of visceral metastases and poor performance status, were associated with worse prognosis in mixed histology tumors.
  • CONCLUSION: Non-transitional histology does not predict for an inferior survival after platinum-based chemotherapy for advanced urothelial carcinoma.
  • Well-known prognostic factors in transitional cell carcinomas were also associated with prognosis in mixed carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094415.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


2. Pardo J, Murcia M, García F, Alvarado A: Gliosarcoma: A rare primary CNS tumor. Presentation of two cases. Rep Pract Oncol Radiother; 2010;15(4):98-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma: A rare primary CNS tumor. Presentation of two cases.
  • INTRODUCTION: Gliosarcoma is a very rare primary mixed tumor in the central nervous system, with a biphasic pattern consisting of glial and malignant mesenchymal elements.
  • RESULTS: Standard treatment consists in surgical resection of the tumor followed in some cases by external radiotherapy and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24376932.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3863303
  • [Keywords] NOTNLM ; Gliosarcoma / Two cases report
  •  go-up   go-down


3. Sharon E, Kelly RJ, Szabo E: Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol; 2010;2:12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
  • BACKGROUND: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis.
  • Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy.
  • We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine.
  • CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy.
  • Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid.
  • He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution.
  • Continued treatment has resulted in maintenance of disease control for over 2 years.
  • CONCLUSION: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy.
  • In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3246-50 [17577021.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):309-19 [18544445.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):923-7 [1353853.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • (PMID = 20504363.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889991
  •  go-up   go-down


Advertisement
4. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • They have a generally poor prognosis and often develop recurrent disease.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


5. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mixed tumor].
  • The term "malignant mixed tumor" is usually synonymous with "carcinoma in pleomorphic adenoma," a secondary carcinoma developing in pre-existing pleomorphic adenoma.
  • However, it sometimes indicates a group of tumors consisting of carcinoma in pleomorphic adenoma, carcinosarcoma (true malignant mixed tumor) and metastasizing benign mixed tumor, the latter 2 being the most infrequent.
  • According to the data of the Japanese committee on TNM classification for salivary gland carcinomas, carcinoma in pleomorphic adenoma accounted for about 10% of all salivary gland carcinomas, both in the parotid and submandibular glands.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-major] Mixed Tumor, Malignant. Salivary Gland Neoplasms
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Carcinosarcoma / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major salivary gland diseases. Multicentre study.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Benign tumours account for 80% of case histories with a relationship 1:4 M/F, the most frequent being pleomorphic adenoma (57.3% of cases), followed by Warthin's tumour (32.4%), this rating not having been confirmed in case histories (8-10%) in the literature.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • Enucleoresection was limited to approximately 15% of neoplasms, enucleation to <10% of cases with only 2% of pleomorph adenoma due to the well-known anatomo-pathological characteristics which may lead to relapse.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • When no clinically evident lymph nodes were present (NO) considering the tumour histotype, two thirds of patients underwent surgery or radiotherapy, while in the remainder the wait-and-see attitude was prefered.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-major] Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


7. Martinez-Quintanilla J, Cascallo M, Gros A, Fillat C, Alemany R: Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy. Mol Cancer Ther; 2009 Nov;8(11):3098-107
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy.
  • Thymidine kinase (TK)-mediated suicide gene therapy has been considered for the treatment of pancreatic cancer.
  • However, despite a bystander effect, the proportion of transduced tumor cells has proven too low to result in efficacy.
  • We propose the use of a drug-selectable marker (MDR1) to enrich TK-expressing cells using chemotherapy.
  • This enrichment or positive selection phase may increase the efficacy of suicide gene therapy.
  • Mixed tumors of MDR/TK-expressing cells and parental NP18 cells were established and docetaxel was used to increase the proportion of TK-expressing cells.
  • After this positive selection phase, suicide gene therapy with ganciclovir was applied.
  • Subsequent suicide gene therapy was more effective compared with a control group without positive selection.
  • Starting with 10% of TK-expressing cells the positive-negative selection strategy completely inhibited tumor growth.
  • Taken together, these results suggest that a positive-negative selection strategy based on MDR and TK genes represents an efficient way to increase the proportion of TK-expressing cells in the tumor and the efficacy of TK-mediated suicide gene therapy.
  • [MeSH-major] Ganciclovir / pharmacology. Genes, Transgenic, Suicide. Genetic Therapy / methods. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / therapy. Taxoids / pharmacology. Thymidine Kinase / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / therapy. Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Combined Modality Therapy. Genetic Vectors. Humans. Male. Mice. Mice, Inbred BALB C. P-Glycoprotein / biosynthesis. P-Glycoprotein / genetics. P-Glycoprotein / metabolism. P-Glycoproteins. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887556.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


8. Gelos M, Behringer D, Philippou S, Mann B: Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature. JOP; 2008;9(1):50-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature.
  • CONTEXT: Carcinosarcoma (malignant mixed tumor) is a rare variant of a pancreatic neoplasm having a dismal prognosis; very few clinical data and treatment options have been published.
  • Unlike adenocarcinoma of the pancreas, there is nothing specific in the literature for this variant regarding postoperative treatment with chemotherapeutic agents.
  • CASE REPORT: We report the case of a 61-year-old woman presenting with anemia.
  • CONCLUSION: Carcinosarcoma of the pancreas is a very rare disease having a dismal prognosis.
  • In addition to reviewing the literature on this entity, we present the first published case where gemcitabine was administered as a treatment modality in combination with surgery.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / surgery. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182744.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 14
  •  go-up   go-down


9. Khadse P, Prabhash K, Pramesh CS, Chaturvedi P, Shet T: Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma. Diagn Cytopathol; 2009 Sep;37(9):680-5
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
  • Malignant mixed tumor of the parotid is known to have odd sites for metastases.
  • We describe the fine-needle aspiration cytology (FNAC) findings of pleural metastasis from a malignant mixed tumor misdiagnosed as a mesothelioma on cytology at the onset.A 47-year-old man presented to us with breathlessness and a massive pleural effusion with pleural-based nodules.
  • He had been operated 2 years before for a pleomorphic adenoma of the parotid and had a healthy scar at that site.
  • These cells in contrast to the usual mesothelial cells were not arranged in sheets but rather were huddled in places and formed a pseudoacinar pattern and blended with the myxoid substance.After the diagnosis of a mesothelioma, patient received pemetrexed and cisplatin based chemotherapy with partial response.
  • While on chemotherapy tumor recurred at the primary site in parotid and was confirmed to be a carcinosarcoma on a FNAC and biopsy.To conclude, pleural metastases from a true malignant mixed tumor of the parotid gland can be misdiagnosed as mesothelioma and could occur in the absence of uncontrolled disease at primary site.
  • Both mesotheliomas and pleomorphic adenomas metastatic to the pleura are biphasic tumors, but in a patient with history of pleomorphic adenoma, the latter should be kept as a foremost possibility.
  • Attention to the cytomorphology of tumor cells will also assist in confirming the diagnosis.
  • [MeSH-major] Carcinosarcoma / secondary. Mesothelioma / pathology. Neoplasms, Complex and Mixed / secondary. Parotid Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Diagnosis, Differential. Diagnostic Errors. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pemetrexed. Pleural Effusion, Malignant / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373913.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Dumortier J, Freyer G, Sasco AJ, Frappart L, Zénone T, Romestaing P, Trillet-Lenoir V: Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature. Ann Oncol; 2000 Mar;11(3):355-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature.
  • BACKGROUND: Anti oestrogenic treatment is widely used for breast cancer treatment and prevention of recurrence.
  • Although secondary endometrial cancers usually present as pure adenocarcinomas, other types of rare tumors have also been reported.
  • PATIENTS AND METHODS: Herein we describe the clinical, pathological as well as therapeutic aspects of a new case of endometrial mesodermal mixed tumor occurring after long-term tamoxifen therapy.
  • RESULTS: The present case occured five years after cessation of a five years tamoxifen treatment.
  • The patient failed to respond to doxorubicin and cyclophosphamide when combined to 5-fluorouracil (5-FU), but she reached complete response when the same two drugs were used with carboplatin, suggesting the potential usefullness of platinum derivatives.
  • CONCLUSIONS: A longer latency period might be observed for endometrial mesodermal mixed tumors as compared to adenocarcinomas and could justify a prolonged clinical and ultrasonographic follow-up of patients during and after tamoxifen treatment.
  • When indicated, chemotherapy might require the use of platinum derivatives in this particular type of secondary tumor.

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811505.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin
  • [Number-of-references] 24
  •  go-up   go-down


11. Solomonov A, Rosenblatt E, Ben-Izhak O, Goralnik L, Yigla M: High-dose-rate endobronchial brachytherapy in endobronchial metastatic malignant chondroid syringoma. Respiration; 2001;68(4):406-10
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate endobronchial brachytherapy in endobronchial metastatic malignant chondroid syringoma.
  • A 65-year-old man with malignant chondroid syringoma (MCS) was found to have pulmonary metastases in the form of multiple pulmonary nodules 4 years after wide excision and adjuvant radiotherapy of a primary abdominal wall tumor.
  • Atelectasis of the lingula due to obstructive endobronchial metastasis, resistant to combination chemotherapy, led us to perform high-dose rate (HDR) endobronchial brachytherapy for the first time in this rare tumor with a favorable response.
  • This case emphasizes the role of HDR brachytherapy as a palliative procedure in endobronchial tumors not responding to other treatment modalities, even those considered to be radioresistant.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / radiotherapy. Brachytherapy. Bronchial Neoplasms / radiotherapy. Bronchial Neoplasms / secondary. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Syringoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11464090.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Takahashi H, Ishiko A, Kobayashi M, Tanikawa A, Takasu H, Md MT: Malignant chondroid syringoma with bone invasion: a case report and review of the literature. Am J Dermatopathol; 2004 Oct;26(5):403-6
Genetic Alliance. consumer health - Syringoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant chondroid syringoma with bone invasion: a case report and review of the literature.
  • We describe a 27-year-old Japanese female with a recurrent nodule on the left big toe and local bone invasion.
  • Histopathologically, the tumor consisted of nests of atypical cells with few mitotic cells, which partly formed gland-like structures.
  • Areas of myxoid degeneration, positive for Alcian blue staining and that did not stain after they were digested with hyaluronidase, were prominent in the matrix among tumor cells.
  • Positive staining was noted in tumor cells for cytokeratin (AE1+AE3), S-100 protein, neuron specific enolase (NSE), and glial fibrillary acidic protein (GFAP).
  • These findings, especially positive GFAP staining were characteristic and very helpful for the diagnosis of the rare tumor-malignant chondroid syringoma.
  • Based on the previous reports, 39% of cases were found to have metastatic lesions and 22% died of this malignant tumor.
  • There have been no reports reporting effectiveness of chemotherapy and radiotherapy, and an early wide excision with a broad margin may be the most reliable treatment to date.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Bone and Bones / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15365374.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


13. Trimeche Ajmi S, Chadli Chaieb M, Mokni M, Braham R, Ach K, Maaroufi A, Chaieb L: Corticomedullary mixed tumor of the adrenal gland. Ann Endocrinol (Paris); 2009 Dec;70(6):473-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticomedullary mixed tumor of the adrenal gland.
  • Abdominal magnetic resonance imaging showed a right heterogeneous adrenal mass measuring 4 x 6 cm with mixed component of fat and adrenal tissue suggesting corticosurrenaloma.
  • Histological examination showed a single tumor mass composed of an admixed population of adrenal cortical and medullary cells.
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Gland Neoplasms / diagnosis. Adrenal Medulla / pathology
  • [MeSH-minor] Adipocytes / pathology. Adrenal Insufficiency / drug therapy. Adrenal Insufficiency / etiology. Adrenalectomy / adverse effects. Adult. Amenorrhea. Androgens / blood. Chromogranin A / analysis. Cushing Syndrome. Diagnosis, Differential. Female. Hirsutism. Humans. Hydrocortisone / blood. Hypertension. Hypokalemia. Immunohistochemistry. Magnetic Resonance Imaging. Obesity. Weight Gain

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878923.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgens; 0 / Chromogranin A; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


14. Prigent M, Teissier N, Peuchmaur M, El Maleh-Berges M, Philippe-Chomette P, Cardin P, Orbach D: Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery. Int J Pediatr Otorhinolaryngol; 2010 Aug;74(8):942-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery.
  • Sialoblastoma is a very rare congenital salivary gland tumor.
  • No consensus has been reached concerning the treatment of this tumor due to its rarity.
  • The treatment of reference is surgery, which can be mutilating, in the case of a locally invasive tumor.
  • The treatment of metastatic disease is also controversial.
  • The authors report a new case of a 6-year-old girl with a progressively growing left parotid mass since birth.
  • The first cytological diagnosis was that of pleomorphic adenoma.
  • Six months later, local recurrence and lung metastasis were treated by neoadjuvant chemotherapy with a very good partial response on the local recurrence and the lung metastasis, allowing complete parotidectomy with sacrifice of the facial nerve.
  • Bilateral lung biopsies after adjuvant chemotherapy showed total necrosis.
  • No recurrence was observed with a follow-up of 1 year.
  • This case and a review of the literature confirm the very good chemosensitivity of this tumor and argue in favor of neoadjuvant chemotherapy for locally invasive tumors rather than extensive mutilating surgery.
  • [MeSH-major] Adenoma, Pleomorphic / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Staging. Rare Diseases. Risk Assessment. Salivary Glands / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright (c) 2010. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20554035.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


15. Lee JR, Georgi DE, Wang BY: Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature. Ann Diagn Pathol; 2007 Jun;11(3):190-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature.
  • Myoepithelial tumors of the soft tissues have only recently been described.
  • Two cases of lower extremity malignant myoepithelial tumors are reported.
  • One case of malignant mixed tumor overlying the gastrocnemius muscle was treated with wide local excision, but metastasized to regional lymph nodes 14 months after surgical excision.
  • One patient with malignant myoepithelioma of the right lower leg was treated with limb amputation and is alive without disease at 46 months.
  • A review of the literature discloses 120 additional cases of soft tissue myoepithelial tumors, 102 of which are myoepitheliomas and 18 are mixed tumors.
  • Thirty-seven percent of the myoepitheliomas met the criteria for malignancy, and 33% of the mixed tumors were malignant.
  • Of these, 30% had locally recurrent disease and 32% developed metastatic disease.
  • Treatment benefit from chemotherapy and radiation therapy is unclear.
  • [MeSH-major] Myoepithelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Calcium-Binding Proteins / metabolism. Cell Proliferation. Glial Fibrillary Acidic Protein / metabolism. Humans. Leg / pathology. Male. Microfilament Proteins / metabolism. Middle Aged. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Necrosis / pathology. Phosphopyruvate Hydratase / metabolism. Vimentin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498593.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Microfilament Proteins; 0 / Vimentin; 0 / calponin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 35
  •  go-up   go-down


16. Marjanović S, Cerović S, Brajusković G: [Use of high-dosage chemotherapy with autologous hematopoietic stem cell transplantation as a first-line therapy for the patients with poor-prognosis testicular tumors]. Vojnosanit Pregl; 2005 Mar;62(3):213-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of high-dosage chemotherapy with autologous hematopoietic stem cell transplantation as a first-line therapy for the patients with poor-prognosis testicular tumors].
  • BACKGROUND: High-dose chemotherapy followed by hematopoietic stem cell support can be used as a first-line treatment in patients with germ-cell tumor (GCT) with poor prognosis.
  • The aim of this paper was to present the experience at the Department of Hematology, Military Medical Academy, with high-dose cytostatic therapy as first-line chemotherapy in GCT patients with poor prognosis.
  • METHODS: Between 1997 and 2003, five patients with high-risk germ-cell tumors were treated with high-dosage chemotherapy followed by an autologous stem cell transplantation.
  • All the patients were with non-seminomatous germ-cell tumors with mixed histology, and one was with extragonadal retroperitoneal germ-cell tumor.
  • One patient was with residual tumor resection, using retroperitoneal lymphadenectomy, after autologous stem cell transplantation.
  • CONCLUSION: Early high-dose chemotherapy associated with hematopoietic stem cell support as a first-line treatment in the patients with germ-cell tumor with a poor prognosis, represented an efficient treatment modality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Prognosis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790050.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  •  go-up   go-down


17. Piulats JM Sr, Nadal M, Martinez-Iniesta M, Puertas S, Gonzalez S, Vidal A, Condom E, Germa-Lluch J, Garcia Del Muro X, Villanueva A: Nude mice model of primary human nonseminoma germ cell tumors to study biology and resistance to cisplatin treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e16143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nude mice model of primary human nonseminoma germ cell tumors to study biology and resistance to cisplatin treatment.
  • : e16143 Testicular germ cell tumors (TGCTs) are the most common malignancy in young men.
  • Recently, our group has reported the development of a model of human nonseminoma (NSE) after orthotopic nude mice implantation (Piulats et al, Amer Assoc Cancer Res. 2006).
  • Pure and mix NSE anatomies were represented and they reproduce the main histological, genetic and epigenetic characteristics of paired primary tumors.
  • Xenografts mimic distal dissemination patterns and cisplatin (CDDP) tumor behavior responses.
  • This model has been useful for the study of antiangiogenic therapies (Piulats et al, ASCO.
  • We have generated in vivo five tumors showing increased resistance to CDDP by exposition to repetitive cycles and increasing the dose applied through different passages (1 yolk-sac; 1 choriocarcinoma; 2 embrional carcinoma; 1 mix tumor).
  • A shortness time elipse between pasajes was observed for each tumor through CDDP treatments.
  • To confirm increasin resistance, a parallel assay of chemotherapy response was performed between nontreated and CDDP resistant tumors.
  • Whole genome analysis of tour xenografted tumors and their paired CDDP resistant tumor (#3 and #5 passage) were analyzed by CGH NimbeGen arrays using 60 Kb average windows.
  • Few differential genomic changes were identified some of them were consistent across resistant tumors including gain of 9q21.11-9q33.3, 15q23-15q24.1, and 15q26.3 regions and loss of Xp22.33.
  • In one tumour showing strong CDDP resistance compared with its sensitive counterpart it occur in absence of new genomic changes.
  • No changes in the MSI or mutational TP53 status were observed in resisant tumors.
  • Our data suggest that acquisition of tumor resistance to CDDP in TGCTs may proably depend of a combination of different mechanisms, including cromosomal imbalances.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Brenner B, Shia J, Klimstra DS, Gonen M, Shah MA, Leonard GD, Kelsen DP: High-grade neuroendocrine carcinomas of the gastrointestinal tract: The Memorial Sloan - Kettering Cancer Center experience of 143 cases. J Clin Oncol; 2004 Jul 15;22(14_suppl):4123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary tumor location was in the large bowel.
  • Thirty-eight percent of tumors had non-HGNEC components and 46% presented with extensive disease (ED), according to the VALSG staging system used in pulmonary SmCC.
  • In limited disease (LD), surgery and chemoradiation resulted in a small group of long-term survivors, while chemotherapy was essentially palliative.
  • Using chemotherapy, most commonly platinum and etoposide, a 50% response rate was observed.
  • No significant differences in patient and tumor characteristics nor in outcome were noted between SmCC and LCNEC.
  • Tumors from different locations shared most of their clinicopathological features, although those arising at the upper GIT were found at an earlier stage and tended to have better prognosis.
  • Mixed tumor histology is common and may affect therapy.
  • Response rate to chemotherapy appears lower than expected from the perceived similarity to SmCC of the lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S: The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet; 2000 Apr;263(4):170-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We restudied histologically and immunohistochemically 17 endometrial carcinomas, 2 malignant mixed tumors and 180 endometria with benign changes during or after tamoxifen therapy.
  • None of 11 patients biopsied before starting tamoxifen therapy had advanced endometrial glandular proliferation in the second endometrial biopsy after tamoxifen treatment.
  • None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Mullerian mixed tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrium / drug effects. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy. Carcinosarcoma / chemically induced. Carcinosarcoma / pathology. Carcinosarcoma / ultrasonography. Cystadenocarcinoma, Papillary / chemically induced. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / ultrasonography. Female. Humans. Immunohistochemistry. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / ultrasonography. Polyps. Retrospective Studies. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834325.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


20. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • All these tumors are benign and/or of low-grade malignancy, with the exception of malignant myoepithelioma.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Humans. Middle Aged


21. Kariya S, Kosaka M, Orita Y, Akagi H, Nishizaki K: Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases. Auris Nasus Larynx; 2006 Mar;33(1):43-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases.
  • OBJECTIVE: Adenocarcinoma ex pleomorphic adenoma is a rare tumor, and thus the management of the tumor has not been established.
  • RESULTS: We present five cases of adenocarcinoma ex pleomorphic adenoma of the head and neck, including a rare case with nasopharyngeal adenocarcinoma ex pleomorphic adenoma.
  • There was no response to chemotherapy with nedaplatin and 5-FU, but the nasopharyngeal adenocarcinoma ex pleomorphic adenoma showed a remarkable regression after the administration of docetaxel.
  • CONCLUSION: The combination therapy that includes docetaxel may be a promising treatment for adenocarcinoma ex pleomorphic adenoma of the head and neck.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Mouth Neoplasms / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Palate / pathology. Parotid Gland / pathology. Retrospective Studies. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168590.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae].
  • OBJECTIVE: To investigate the clinical manifestations of lacrimal gland tumor involving the anterior and middle cranial fossae and the effect of transcranial-orbital approach in treatment of such tumor.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • Recurrence of tumor occurred in 4 cases, and 1 case died from distant metastasis of adenocarcinoma.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.
  • Adequate orbital apex decompression and exposure of the tumor can result from suitable transcranial-orbital approach.
  • However, complete surgical excision is difficult, and the tumor has a tendency to recur post-operatively.
  • Suitable treatment strategy should by combination of operation with irradiation or chemotherapy.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Yura S, Terahata S, Ohga N, Yamashita T: A case of carcinosarcoma arising in the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):820-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of carcinosarcoma arising in the submandibular gland.
  • A 54-year-old man presented with an 8-year history of a hard asymptomatic mass of the left submandibular area.
  • Total excision of the left submandibular gland with radical neck dissection was performed under a diagnosis of a submandibular tumor, probably a malignant mixed tumor.
  • In the central area of the tumor, a few remnants of benign pleomorphic adenoma were identifiable.
  • The finding suggested that in our patient, the carcinosarcoma arose from a preexisting pleomorphic adenoma.
  • In view of the expected aggressive nature of the tumor, the patient was treated with postoperative radiotherapy of 60 Gy total, in 30 daily fractions of 2 Gy, and chemotherapy.
  • He currently remains well and free of disease 24 months after treatment.
  • [MeSH-major] Carcinosarcoma / pathology. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531942.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rosenblum M, Mikkelsen T: Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery; 2004 May;54(5):1111-7; discussion 1117-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with malignant glioma previously treated with surgery, radiation, and chemotherapy, clinical and radiographic signs of recurrent disease often require differentiation between radiation necrosis and recurrent tumor.
  • Published work suggests that although magnetic resonance spectroscopy (MRS) can reliably differentiate pure tumor, pure necrosis, and spectroscopically normal tissues, it may not be particularly helpful because most patients have mixed histological findings comprised of necrosis and tumor.
  • METHODS: In 18 patients, spectroscopic and diffusion-weighted images were obtained before surgery for suspected recurrent neoplastic disease.
  • Spectral data for pure tumor, pure necrosis, and mixed tumor and necrosis were derived from 65 spectroscopic observations in patients with previously treated gliomas (n = 16) and metastatic tumors (n = 2).
  • Spectral data for choline (Cho), N-acetylaspartate (NAA), creatine (Cr), and lipid-lactate were analyzed separately and in conjunction with ADCs in all patients (15 observations of pure tumor, 33 observations of pure necrosis, and 13 observations of mixed tumor and necrosis).
  • Histological specimens were obtained stereotactically at the time of surgery (<48 h after image acquisition) for recurrent disease and digitally co-registered with MRS data.
  • RESULTS: ADC values for pure tumor, pure necrosis, and mixed tumor and necrosis were 1.30, 1.60, and 1.42, respectively.
  • Cho/NAA less than 0.20, NAA/normal Cr greater than 1.56, and NAA/Cho greater than 1.32 increase the odds that a tissue biopsy will be pure necrosis versus mixed tumor and necrosis.
  • Although various values of all MRS ratios analyzed may provide positive correlations for histopathological differentiation of tissue between that of pure tumor and that of pure necrosis, the addition of ADC values to only NAA/Cho and NAA/normal Cr increases the odds of correct differentiation between pure tumor and pure necrosis.
  • The addition of ADC values does not provide additional information beyond that of MRS in distinguishing specimens of mixed tumor and necrosis from either pure tumor or pure necrosis.
  • CONCLUSION: It has been demonstrated that MRS ratio analysis may allow for the clinical discrimination between specimens of pure tumor and pure necrosis, and the addition of ADC data into this analysis may enhance this specific differentiation.
  • However, although a trend toward correlation between ADC values and the various histopathological features was noted, the direct addition of ADC data does not seem to allow further discrimination, beyond that provided by MRS, among specimens of mixed tumor and necrosis and either pure tumor or pure necrosis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15113465.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hadjistilianou T, de Francesco S, Signori C, Menicacci F, Galluzzi P, Toti P: Pleomorphic adenoma of the lacrimal gland in an 18-year-old girl irradiated for bilateral retinoblastoma. Orbit; 2006 Mar;25(1):51-3
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the lacrimal gland in an 18-year-old girl irradiated for bilateral retinoblastoma.
  • PURPOSE: To report a case of pleomorphic adenoma of the lacrimal gland following irradiation for bilateral retinoblastoma.
  • A 4-month-old girl, with bilateral retinoblastoma, underwent enucleation of the right eye, systemic chemotherapy and bilateral external beam irradiation with a lateral field.
  • 17 years later, she developed a mass in the superotemporal quadrant of the left orbit.
  • RESULTS: Pleomorphic adenoma is rare in children and teenagers; it usually presents as a painless, slow growing mass in healthy adults.
  • In this case, it developed as a second primary tumor after irradiation for retinoblastoma.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lacrimal Apparatus / pathology. Neoplasms, Radiation-Induced / pathology. Retinal Neoplasms / radiotherapy. Retinoblastoma / radiotherapy. Retinoblastoma / secondary
  • [MeSH-minor] Adolescent. Biopsy, Needle. Eye Enucleation. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Risk Assessment. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527777.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Anraku M, Waddell TK: Surgery for small-cell lung cancer. Semin Thorac Cardiovasc Surg; 2006;18(3):211-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of small-cell lung cancer (SCLC) is typically chemotherapy with or without radiation, depending on the extent of disease.
  • Patients with clinical stage T1-2 N0 SCLC may benefit from surgery for confirmation of diagnosis and improved local control when combined with chemotherapy.
  • In this view, mediastinoscopy is recommended to exclude N2 disease before surgery is considered.
  • Patients with a combined histology tumor (mixtures of SCLC with non-SCLC components) may be offered surgery since the non-SCLC component is less sensitive to chemotherapy and resection may contribute to cure.
  • Salvage surgery should be considered for patients having relapse only in the primary site or a localized chemotherapy-resistant tumor, which can occur because of an unrecognized mixed tumor.
  • Recent evidence has shown that platinum-based chemotherapy with concurrent hyperfractionated radiotherapy followed by surgery is feasible and a promising strategy for highly selected patients with SCLC.
  • Among patients with nodal disease, only those with negative nodes following induction chemo/chemoradiotherapy should be candidates for surgery, which may offer improved local control.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185181.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


27. Beijer S, Hupperets PS, van den Borne BE, Wijckmans NE, Spreeuwenberg C, van den Brandt PA, Dagnelie PC: Randomized clinical trial on the effects of adenosine 5'-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients. J Pain Symptom Manage; 2010 Oct;40(4):520-30
Hazardous Substances Data Bank. Lactose .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the effects of ATP infusions on QoL parameters in patients with preterminal cancer of mixed tumor types.
  • Unexpectedly, in the untreated control group, most of the outcome parameters did not deteriorate but remained stable or even significantly improved over time.
  • CONCLUSION: ATP infusions, at the dose and schedule studied, did not have a significant effect on QoL, functional status, or fatigue in preterminal cancer patients of mixed tumor types.
  • [MeSH-major] Adenosine Triphosphate / therapeutic use. Fatigue / complications. Fatigue / drug therapy. Neoplasms / complications. Quality of Life
  • [MeSH-minor] Activities of Daily Living. Aged. Aged, 80 and over. Analysis of Variance. Female. Health Status. Humans. Lactose / analogs & derivatives. Methacrylates. Middle Aged. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20598849.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-O-methacryloyloxyethoxyl-(2,3,4,6-tetra-O-acetylgalactopyranosyl)-(1-4)-2,3,6-tri-O-acetylglucopyranoside; 0 / Methacrylates; 8L70Q75FXE / Adenosine Triphosphate; J2B2A4N98G / Lactose
  •  go-up   go-down


28. Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H: A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer; 2006 May-Jun;16(3):972-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine papillary serous carcinoma (UPSC) accounts for 10% of endometrial carcinomas but a higher proportion of deaths due to its aggressive nature and poor response to chemotherapy and radiotherapy.
  • The percentage of UPSC in the tumors did not affect the outcome.
  • Stage, positive omentum, and treatment with external-beam +/- intracavitary radiotherapy were significantly correlated with overall survival and progression-free survival by univariate analysis, but only stage (P < 0.01) was correlated with outcome on multivariate analysis.
  • Chemotherapy did not affect outcome.
  • UPSC may be difficult to diagnose in preoperative biopsies, particularly when present as part of a mixed tumor.
  • Even a small percentage of UPSC in a diagnostic biopsy or hysterectomy specimen is correlated with a poor prognosis.
  • This study emphasizes the need of a cooperative, prospective study on this distinct uterine carcinoma.
  • [MeSH-major] Carcinoma, Papillary / etiology. Carcinoma, Papillary / therapy. Uterine Neoplasms / etiology. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / radiotherapy. Disease-Free Survival. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / etiology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / radiotherapy. Female. Humans. Hysterectomy / statistics & numerical data. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Ovariectomy / statistics & numerical data. Radiotherapy, Adjuvant. Retrospective Studies. Salpingostomy / methods. Salpingostomy / statistics & numerical data. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803471.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Damiano R, D'Armiento M, Cantiello F, Amorosi A, Tagliaferri P, Sacco R, Venuta S: Gemcitabine and cisplatin following surgical treatment of urinary bladder carcinosarcoma. Tumori; 2004 Sep-Oct;90(5):458-60
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and cisplatin following surgical treatment of urinary bladder carcinosarcoma.
  • The clinical case of a 73-year-old man with a history of transitional cell carcinoma of the bladder, an ulcerated mass on the left hemitrigone and left hydronephrosis who underwent radical cystoprostatectomy and urinary diversion followed by cisplatin-gemcitabine chemotherapy is presented.
  • Pathological examination revealed a biphasic mixed tumor characterized by an epithelial and a mesenchymal component.
  • At 24 months of follow-up the patient is alive and free from recurrent disease, with good quality of life and preserved renal function.
  • Carcinosarcoma is highly aggressive and often has a dismal outcome regardless of treatment.
  • The outcome of our patient suggests that the relatively well tolerated gemcitabine-cisplatin regimen after surgical treatment of invasive carcinosarcoma of the bladder might improve the currently dismal prognosis of selected elderly patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / surgery. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Humans. Male. Prognosis. Prostatectomy. Treatment Outcome. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656328.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Ishida M, Hasegawa M, Kanao K, Oyama M, Nakajima Y: Non-palpable testicular embryonal carcinoma diagnosed by ultrasound: a case report. Jpn J Clin Oncol; 2009 Feb;39(2):124-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the extensive use of scrotal ultrasound (US), incidental non-palpable testicular tumors have thus been unexpectedly discovered.
  • This report documents the case of 24-year-old male with a non-palpable testicular tumor that contained non-seminomatous germ cell components detected by US.
  • Radical orchiectomy was performed and histological examinations confirmed a diagnosis of a mixed tumor of seminoma and embryonal carcinoma.
  • Systemic chemotherapy was introduced immediately, and the serum level of AFP decreased to the normal range and the metastatic lesions had disappeared after three courses of the chemotherapy.
  • No recurrence was observed at 18 months follow-up after the chemotherapy.

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066212.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol; 2010 May;223(2):384-8
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane.
  • The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer.
  • We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes.
  • None of the patients received chemotherapy or radiation therapy before or after surgery as a part of an adjuvant or neoadjuvant program.
  • On univariate survival analysis, the hENT1 expression was associated with overall survival (OS) and disease free survival (DFS).
  • Furthermore, considering only patients with diffuse or mixed tumors and lymph-node positive, the expression of hENT1 was strongly related with DFS and OS.
  • Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Equilibrative Nucleoside Transporter 1 / metabolism. Gastric Mucosa / metabolism. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Cohort Studies. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / physiopathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082300.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Equilibrative Nucleoside Transporter 1; 0 / SLC29A1 protein, human
  •  go-up   go-down


32. Kummoona R: Periorbital and orbital malignancies: methods of management and reconstruction in Iraq. J Craniofac Surg; 2007 Nov;18(6):1370-5
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were squamous cell carcinoma, basal cell carcinoma, conjunctival squamous cell carcinoma, retinoblastoma, fibrosarcoma, and ectopic mixed tumor in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.
  • Eight patients were treated surgically with adjuvant postoperative radiotherapy, whereas eight patients with lymphoma treated with combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, methotrexate, and prednisolone), the survival rate was very poor.
  • Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the tumor in four patients.
  • There is no single best method for reconstruction of the periorbital and orbital defects left after tumor resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993883.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Huang R, Jaffer S: Imprint cytology of metastatic sialoblastoma. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1123-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sialoblastoma is a rare, aggressive and potentially malignant perinatal/congenital tumor that recapitulates the developing salivary gland.
  • CASE: A 75-month-old girl with a history of recurrent sialoblastoma initially diagnosed at 21 months and treated with multiple incomplete surgical excisions, chemotherapy and radiation presented with a solitary lung nodule.
  • The clusters contained admixed benign ductal cells and dense, metachromatic, magenta hyaline globular material with smooth, rounded outlines.
  • The differential diagnoses include neoplasms composed of either basaloid cells and/or admixed hyaline matrix material and included pleomorphic adenoma, basal cell adenoma and adenoid cystic carcinoma.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Disease Progression. Epithelial Cells / pathology. Female. Humans. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Parotid Gland / pathology. Parotid Gland / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674095.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Wick W, Weller M: [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. Nervenarzt; 2010 Aug;81(8):928-30, 932-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the current WHO classification anaplastic gliomas comprise pure astrocytomas and oligodendrogliomas and mixed tumors.
  • The molecular subgroup analyses of the NOA-04 trial identified three molecular parameters, which predict longer progression-free and overall survival independent from the mode of therapy, radiotherapy or alkylating chemotherapy-.
  • Therefore, marker profiles should be included into the next WHO brain tumor classification.
  • The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.
  • The next steps, e.g. within the international CATNON trial, are to define the role and optimal sequencing of combined modality treatment focusing on radiotherapy and temozolomide.
  • Furthermore, anaplastic gliomas are an important group of brain tumors for developing future molecular targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at improved efficacy and avoiding long-term side-effects.
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Chromosome Deletion. Clinical Trials as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Cranial Irradiation. DNA Modification Methylases / genetics. DNA Mutational Analysis. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Isocitrate Dehydrogenase / genetics. Promoter Regions, Genetic / genetics. Survival Rate. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] J Neurol. 2009 May;256(5):734-41 [19240962.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Cancer Res. 2009 May 15;69(10 ):4502-9 [19366800.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1210-6 [18248979.001]
  • [Cites] J Neurooncol. 2009 May;92(3):401-15 [19357966.001]
  • [Cites] J Clin Oncol. 2010 Apr 20;28(12 ):2051-7 [20308655.001]
  • [Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):1019-24 [18676355.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):330-5 [18240930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • (PMID = 20635074.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


35. Beijer S, Hupperets PS, van den Borne BE, Eussen SR, van Henten AM, van den Beuken-van Everdingen M, de Graeff A, Ambergen TA, van den Brandt PA, Dagnelie PC: Effect of adenosine 5'-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs; 2009 Aug;20(7):625-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-nine preterminal cancer patients (estimated life expectancy 1-6 months) with mixed tumor types were randomly allocated to receive either intravenous ATP weekly (8-10 h/week, maximum 50 microg/kg/min) for 8 weeks, or no ATP (control group).
  • Larger studies are warranted to confirm these findings and to further define the effect of ATP on tumor growth and survival.
  • [MeSH-major] Adenosine Triphosphate / therapeutic use. Cachexia / drug therapy. Neoplasms / complications. Nutritional Status / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491658.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


36. Ohba S, Fujimori M, Ito S, Matsumoto F, Hata M, Takayanagi H, Wada R, Ikeda K: A case report of metastasizing myoepithelial carcinoma of the parotid gland arising in a recurrent pleomorphic adenoma. Auris Nasus Larynx; 2009 Feb;36(1):123-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of metastasizing myoepithelial carcinoma of the parotid gland arising in a recurrent pleomorphic adenoma.
  • Myoepithelial carcinoma, arising in a recurrent or in a pre-existing pleomorphic adenoma of the parotid gland is an extremely rare cancer.
  • We herein report the case of myoepithelial carcinoma occurring in a recurrent pleomorphic adenoma, which showed a high metastatic potential.
  • A 53-year-old male, who had undergone a superficial parotidectomy of the pleomorphic adenoma 2 years previously, presented with recurrent parotid swelling and with multiple coin lesions in the lung.
  • The patient died about 12 months later despite undergoing intensive chemotherapy.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lung Neoplasms / secondary. Myoepithelioma / pathology. Neoplasms, Second Primary / pathology. Parotid Neoplasms / pathology. Solitary Pulmonary Nodule / secondary
  • [MeSH-minor] Humans. Male. Middle Aged. Parotid Gland / surgery

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650039.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Güler E, Tezer Kutluk M, Büyükpamukçu N, Caglar M, Varan A, Akyüz C, Büyükpamukçu M: Testicular germ cell tumors in childhood: treatment results of 52 patients. Pediatr Hematol Oncol; 2004 Jan-Feb;21(1):49-56
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumors in childhood: treatment results of 52 patients.
  • We analysed the treatment results of 52 children with testicular germ cell tumors.
  • Histopathological diagnoses were endodermal sinus tumor (63.4%), embryonal carcinoma (28.8%), teratocarcinoma (5.7%), and mixed tumors (2.1%).
  • Five-year overall survival rates were 85.8% and 100% for stage I patients who received chemotherapy or not (p =.27); BEP regimen: 85.7%; classical VAC: 67.9%; vinblastine + bleomycin: 63.6%.
  • Chemotherapy is not required in stage I.
  • BEP regimen is effective in testicular germ cell tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Male. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14660306.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Uruga H, Fujii T, Kurosaki A, Hanada S, Takaya H, Miyamoto A, Morokawa N, Kishi K: [A case of pulmonary tumor thrombotic microangiopathy caused by carcinoma (salivary duct carcinoma) ex pleomorphic adenoma]. Nihon Kokyuki Gakkai Zasshi; 2010 Jun;48(6):463-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary tumor thrombotic microangiopathy caused by carcinoma (salivary duct carcinoma) ex pleomorphic adenoma].
  • A 53-year-old man with carcinoma (salivary duct carcinoma) ex pleomorphic adenoma was admitted to our hospital because of dyspnea.
  • He received chemotherapy in July 2007, and was subsequently followed up without chemotherapy.
  • An autopsy was performed, and microscopic examination revealed tumor cell embolism, intimal fibrocellular proliferation of the small arteries, fibrin thrombi and recanalization.
  • A diagnosis of pulmonary tumor thrombotic microangiopathy (PTTM) was made.
  • Immunohistochemical staining of the tumor cells for VEGF was weakly positive.
  • To the best of our knowledge this is the first reported case of PTTM caused by a salivary gland tumor.
  • [MeSH-major] Carcinoma / complications. Lung Neoplasms / complications. Salivary Ducts. Salivary Gland Neoplasms / complications. Thrombotic Microangiopathies / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20608093.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • Serum CA125 level was found to be elevated in 22 of the 34 examined cases (64.7%) with a median value of 500 U/ml (range, 39-3439 U/ml).
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


40. Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res; 2006 Apr 15;12(8):2526-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
  • Additional patients showed evidence of lesional regression (mixed tumor response) or overall regression that did not achieve partial response status (minor response).
  • In vitro evidence of enhanced immunity against tyrosinase following protocol treatments was documented in 3 of 49 (6%) patients tested serologically, 3 of 23 (13%) patients tested for T-cell recognition of individual tyrosinase peptides, and 4 of 16 (25%) patients tested for T-cell recognition of full-length tyrosinase protein with real-time reverse transcription-PCR techniques.
  • CONCLUSIONS: Whereas prime/boost immunization with recombinant vaccinia and fowlpox viruses enhanced antityrosinase immunity in some patients with metastatic melanoma, it was ineffective alone in mediating clinical benefit, and in combination with IL-2 did not mediate clinical benefit significantly different from that expected from treatment with IL-2 alone.
  • [MeSH-major] Cancer Vaccines / immunology. DNA, Recombinant / immunology. Immunization, Secondary / methods. Interleukin-2 / therapeutic use. Melanoma / therapy. Vaccination / methods
  • [MeSH-minor] Combined Modality Therapy. Genetic Vectors / genetics. Humans. Immunization Schedule. Immunoglobulin G / blood. Interferon-gamma / genetics. Interferon-gamma / metabolism. Monophenol Monooxygenase / genetics. Monophenol Monooxygenase / immunology. Monophenol Monooxygenase / metabolism. Neoplasm Metastasis. Poxviridae / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3124-6 [8205528.001]
  • [Cites] Eur J Immunol. 1994 Mar;24(3):759-64 [8125142.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4685-92 [7722321.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1343-8 [7543520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8125-9 [7667256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Eur J Immunol. 1996 Jan;26(1):224-30 [8566071.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):1965-71 [8642306.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 [8876137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53 [8876138.001]
  • [Cites] Curr Opin Immunol. 1996 Oct;8(5):628-36 [8902387.001]
  • [Cites] Vaccine. 1997 Apr-May;15(6-7):759-68 [9178479.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601 [9362157.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):296-301 [9443408.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2099-106 [9498746.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6985-92 [9862734.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4446-8 [15483013.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4474-85 [15542798.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1218-27 [15718319.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6043-53 [16087944.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):755-9 [10597191.001]
  • [Cites] Vaccine. 2000 Apr 3;18(19):2015-22 [10706963.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44 [10944556.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):252-7 [10966567.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3964-73 [11099326.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1848-54 [11251017.001]
  • [Cites] J Immunother. 2001 May-Jun;24(3):212-20 [11394498.001]
  • [Cites] Eur J Immunol. 2001 Sep;31(9):2690-701 [11536167.001]
  • [Cites] Clin J Oncol Nurs. 2001 Sep-Oct;5(5):207-17 [11905416.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Immunol Methods. 2002 Aug 1;266(1-2):87-103 [12133625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):188-94 [12569574.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2973-80 [12912944.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1595-9 [14996715.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2122-32 [15169798.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3989-96 [15459222.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5 [2679456.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4651-7 [7722317.001]
  • (PMID = 16638862.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z01 SC003811-32; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / DNA, Recombinant; 0 / Immunoglobulin G; 0 / Interleukin-2; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma; EC 1.14.18.1 / Monophenol Monooxygenase
  • [Other-IDs] NLM/ NIHMS35505; NLM/ PMC2151202
  •  go-up   go-down


41. El Sayed S, Grando JP, Almeida SH, Mortati Neto N, Moreira HA: Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection. Int Braz J Urol; 2004 Sep-Oct;30(5):384-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
  • PURPOSE: To determine the role of RPLND for residual masses following chemotherapy in patients with non-seminomatous germ cell tumors (NSGCT) stage T1N2 and T1N3 (IIB and IIC).
  • MATERIALS AND METHODS: We have preformed retrospective analysis of 11 patients who underwent RPLND for residual masses following chemotherapy in an oncologic reference center between January 1997 and December 2002.
  • All patients harbored either pure nonseminomatous or mixed tumors in the testis tissue and had undergone 4 cycles of primary chemotherapy with bleomycin, etoposide and cisplatin.
  • The residual masses were assessed by abdominal computed tomography preoperatively.
  • All patients had tumors in the final pathological report and were referred to other 2 cycles of chemotherapy with the same drugs.
  • Seven patients (63.3%) had complete response and remained free of the disease in a mean follow up of 38.3 months (ranging from 12 to 72).
  • The remaining 3 patients had disease progression, 2 of which died 6 and 12 months after surgery, respectively, and one patient missed the follow-up after salvage chemotherapy.
  • CONCLUSION: Retroperitoneal lymph node dissection for residual masses after chemotherapy is a high-morbidity procedure, even by experienced surgeons, although it remains an efficient modality of treatment in advanced germ cell carcinoma.
  • The high frequency of tumor found in the RPLFN following chemotherapy might have been caused by the small number of patients in this study.
  • [MeSH-major] Germinoma / drug therapy. Germinoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610570.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


42. Simon D, Knebel JW, Baumgartner W, Aufderheide M, Meyer-Lindenberg A, Nolte I: In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. Am J Vet Res; 2001 Nov;62(11):1825-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs.
  • OBJECTIVE: To determine the 50% inhibitory concentration (IC-50) of carboplatin, cisplatin, and doxorubicin in cell cultures of mammary gland tumors obtained from dogs and to assess whether in vitro efficacy was within the range of clinically relevant concentrations, SAMPLE POPULATION: 30 mammary gland tumors excised from dogs.
  • PROCEDURE: Cell cultures were established from the 30 tumors.
  • Growth inhibition of cultures was assessed via DNA measurement 24, 48, and 72 hours after treatment.
  • We did not detect differences in the in vitro susceptibility among subtypes of tumors (ie, adenocarcinoma, solid carcinoma, malignant mixed tumor).
  • CONCLUSION AND CLINICAL RELEVANCE: The IC-50 values determined in this study allowed assessment of in vitro drug efficacy of chemotherapeutics in cultures of mammary gland tumors obtained from dogs.
  • Variations in susceptibility were evident and emphasize the importance of assessing susceptibility and resistance patterns for each tumor.
  • Prospective studies to assess direct correlations between in vitro and in vivo efficacy must be performed to determine the clinical predictive value of this in vitro chemosensitivity assay for treatment of dogs with mammary gland tumors.
  • [MeSH-major] Adenocarcinoma / veterinary. Antineoplastic Agents / pharmacology. Dog Diseases / drug therapy. Mammary Neoplasms, Animal / drug therapy. Mixed Tumor, Malignant / veterinary
  • [MeSH-minor] Animals. Carboplatin / pharmacology. Cisplatin / pharmacology. DNA, Neoplasm / analysis. DNA, Neoplasm / biosynthesis. Dogs. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Female. Immunohistochemistry / veterinary. Inhibitory Concentration 50. Statistics, Nonparametric. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11703031.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Lee SJ, Choi YL, Lee EJ, Kim BG, Bae DS, Ahn GH, Lee JH: Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):248-53
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included five LMS, seven endometrial stromal sarcomas, and five uterine carcinosarcomas (malignant mullerian mixed tumor [MMMT]).
  • Formalin-fixed, paraffin-embedded tissue sections were immunostained with anti-Capn6 domain-II (anti-DII) and anti-Capn6 domain-T (anti-DT) antibodies.
  • All 17 tumors expressed the Capn6 protein; this finding was in contrast to the absence of expression of the Capn6 protein in all of the normal control tissues.
  • There were no significant associations between tumor stage and staining intensity by anti-DII (P= 1.000) or anti-DT (P= 0.576).
  • However, there was a marginally significant association between tumor subtype and staining intensity (P= 0.054 and P= 0.053, respectively).
  • The expression of Capn6 had no association with disease-free survival (P= 0.367 and P= 0.166, respectively).
  • This study showed that there were marginally significant associations between tumor subtypes and staining intensity, but no association was found with tumor stage and survival.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291261.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.22.- / Calpain
  •  go-up   go-down


44. Schmidt P, Haas RJ, Göbel U, Calaminus G: [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update]. Klin Padiatr; 2002 Jul-Aug;214(4):167-72
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
  • [Transliterated title] Risikoadaptierte Therapie-Strategie bei malignen Hodentumoren im Kindesalter - Die MAHO-Studien: Rückblick und aktueller Stand.
  • BACKGROUND: The MAHO studies for treatment of testicular germ cell tumors in childhood and adolescence registered between 1982 and 1/2001 260 patients (pts.).
  • Delay of chemotherapy in YST of stage I A. 2. Delay of modified lymphadenectomy for staging in I A tumors.
  • 3. Stepwise reduction of therapy in low stage tumors but increasing therapy in tumors of metastatic pattern.
  • Standard therapy consisted of 4 courses of vinblastine, bleomycin and cisplatin.
  • In stage II C or higher chemotherapy included cisplatin, VP 16 and bleomycin.
  • As salvage therapy VP16, ifosfamide and cisplatin was given.
  • RESULTS: According to histology and stage only 75/260 pts. needed chemotherapy.
  • Out of 140 pts. with YST 139 survived disease free according to a "watch and wait" policy.
  • 16 of these patients (13 %) needed a delayed standard chemotherapy 6 - 60 weeks after orchiectomy.
  • 59 pts. suffered from other malignant non-seminomatous tumors (EC, chorio, mixed tumors).
  • 20 of these had a clinical stage I including 5 with a pathologic stage I A. 15 received adjuvant chemotherapy and all 20 pts. survived relapse-free.
  • 22 pts. had stage II, 8 of these received salvage therapy in addition to standard chemotherapy, 21 of 22 pts. survived.
  • 17 pts. had stage III or IV, 5 of these died despite receiving salvage therapy, 9 pts. survived in complete remission, 3 pts. had partial remission.
  • Both patients with a seminoma (stage I) survived.
  • In summary, the probability of disease free survival of 260 pts. is 97 % after a median observation time of 60 months.
  • CONCLUSION: In alpha-fetoprotein producing YST tumors of clinical stage I A after semincastratio the "watch and wait" surveillance strategy is found to be optimal.
  • Only about 13 % of these patients had to be treated by chemotherapy at a later time point and thus could be cured.
  • For YST pts. of stages greater than stage I A and all other malignant testicular tumors in childhood effective chemotherapy exists with an overall cure rate of about 95 %.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Drug Administration Schedule. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Male. Neoplasm Staging. Orchiectomy. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165897.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • The resected tumor measuring over 20 cm in diameter consisted of cystic and solid components and was very fragile.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • There was no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin.
  • In spite of aggressive combination chemotherapy and three times of laparotomy, the patient died of disease 3 years 10 months after the initial treatment.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


46. Liao Q, Wang J, Han J: [Clinical and pathological analysis on 106 cases with uterine sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2001 Feb;36(2):104-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the clinical features and factors affecting the prognosis of uterine sarcoma with different histological types.
  • METHODS: One hundred and six cases with uterine sarcoma treated were analyzed retrospectively, among which there were 67 cases with leiomyosarcoma (63.2%), 23 with malignant endometrial interstitial sarcomas (21.7%), 16 with malignant Mullerian mixed tumor (15.1%).
  • The patients usually manifested with abnormal vaginal bleeding (67.0%), palpable mass of lower abdomen (32.1%), vaginal discharge (27.4%), pain on lower abdomen (28.4%), symptoms of oppression (25.5%), and discomfort feeling (28.3%). (2) The rate of preoperative diagnosis was 65.9%, especially that of leiomyosarcoma was lowest (42.9%). (3) In treatment, 16.0% of patients was treated by hysterectomy; bilateral salpingo-oophorectomy and pelvic lymphadenectomy; 75.5% of them by hysterectomy and bilateral salpingo-oophorectomy; after operation, 74.5% of them were treated by chemotherapy, 11.3% by radiotherapy, 6.6% by additional progesterone. (4) The survival period of the patients was related to pathologic types and clinical stages and ages of the patients.
  • The prognosis of uterine sarcoma is related to pathologic types, clinical stage and ages of the patients.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783345.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Lenhard SM, Untch M, Himsl I, Ditsch N, Bittmann I, Friese K, Bauerfeind I: The high-grade endometrial sarcoma: a rare entity. Arch Gynecol Obstet; 2006 Apr;274(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: With an estimated incidence of one to two per one million women, the endometrial stromal sarcoma (ESS) is a rare disease.
  • It is subclassified into a high-grade and a prognostically better low-grade type.
  • Evidence-based data for a standardized therapy is lacking.
  • A fractioned curettage yielded a differential diagnosis of malignant muellerian mixed tumor or a non-differentiated endometrial sarcoma.
  • For completion of the operative treatment, laparotomy with hysterectomy, adnexectomy, and pelvine lymphonodectomy were performed.
  • The final histological report described a 7 cm non-differentiated endometrial sarcoma with infiltration of the left ovary and 25 tumor-free lymph nodes.
  • DISCUSSION: Standard therapy for resectable sarcoma is abdominal hysterectomy and bilateral adnexectomy.
  • So far, there is little data from studies reporting radio- or chemotherapy treatment of small patient numbers in an adjuvant setting.
  • CONCLUSION: The ESS is a very rare disease of the uterus.
  • Due to missing clinical data, it remains a multidisciplinary therapeutic challenge requiring individual decisions.
  • To receive more information on this rare disease, treatment should be performed according to international protocols.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy. Metrorrhagia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311750.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery; 2002 Oct;51(4):912-9; discussion 919-20
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The differentiation of tumor recurrence from radiation necrosis in patients with malignant gliomas who have been treated previously remains a challenge.
  • Magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography cannot provide definitive histopathological insight.
  • METHODS: Twenty-seven patients who had been treated previously with surgery, radiotherapy, and chemotherapy and reoperated for clinical and/or radiographic signs that caused suspicion for recurrent disease were studied.
  • Tissues were categorized into four groups: spectroscopically normal, pure tumor, mixed tumor and radiation necrosis, and pure radiation necrosis.
  • Logistic regression analysis was performed on the basis of data obtained from 99 (1)H MRSI observations to determine whether the (1)H MRSI ratios varied according to tissue category.
  • RESULTS: (1)H MRSI ratios were found to distinguish pure tumor from pure necrosis.
  • The odds of a biopsy's being pure tumor and having either a Cho/nCr value greater than 1.79 or a Lip-Lac/Cho value less than 0.75 are seven times the odds of that biopsy's being pure necrosis (odds ratio, 7.00; P = 0.0136).
  • The odds of a biopsy's being pure necrosis and having either a Cho/nCr value less than 0.89 or a Cho/nCho value less than 0.66 are six times the odds of that biopsy's being pure tumor (odds ratio, 5.71; P = 0.0329).
  • The odds of a biopsy's being pure necrosis and having either a Lip-Lac/Cho value greater than 1.36 or a Lip-Lac/nCr value greater than 2.84 are more than five times the odds of the biopsy's being pure tumor (odds ratio, 5.25; P = 0.0322).
  • In addition, although only marginally significant, Lip-Lac/Cho and Lip-Lac/nCr ratios distinguish pure tumor from pure necrosis.
  • No values suggested that mixed specimens could be distinguished in a statistically significant way from either pure tumor or pure necrosis.
  • CONCLUSION: The data that we gathered suggest that metabolite ratios derived on the basis of (1)H MRSI spectral patterns do allow reliable differential diagnostic statements to be made when the tissues are composed of either pure tumor or pure necrosis, but the spectral patterns are less definitive when tissues composed of varying degrees of mixed tumor and necrosis are examined.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234397.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


49. Kalaitzis C, Bantis A, Tsakaldimis G, Giannakopoulos S, Sivridis E, Touloupidis S: Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report. J Med Case Rep; 2009;3:8702

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report.
  • INTRODUCTION: Late relapse of a testicular germ cell tumour is an uncommon occurrence.
  • We report a case of osteolytic bone metastasis appearing 23 years after the initial treatment of a metastatic testicular mixed tumour (choriocarcinoma and embryonal carcinoma).
  • CASE PRESENTATION: A 52-year-old Caucasian man who underwent a right inguinal orchiectomy due to testicular tumour in 1984 presented to our outpatient clinic in a generally bad condition of health and with severe pain of his right hip joint and os ischii caused by osteolytic metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):820-7 [16508636.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):41-7 [9093706.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1777-81 [1700077.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):985-8 [3409178.001]
  • [Cites] World J Urol. 2004 Apr;22(1):47-54 [15064970.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • (PMID = 19830236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2737795
  •  go-up   go-down


50. Yuki N, Hijikata Y, Kato M, Kawahara K, Wakasa K: Squamous cell carcinoma as a rare entity of primary liver tumor with grave prognosis. Hepatol Res; 2006 Dec;36(4):322-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma as a rare entity of primary liver tumor with grave prognosis.
  • A 63-year-old male alcoholic was incidentally found to have a 6-cm liver tumor which showed mixed echogenic by sonography and a low-density area with rim enhancement by computed tomography.
  • Tumor biopsy led to a diagnosis of SCC with a sarcomatoid change.
  • The tumor showed fatal rapid growth accompanied by abdominal pain.
  • Transcatheter arterial embolization and chemotherapy were not effective, and the tumor increased to 13cm in diameter over an 8-month period.
  • A post-mortem search revealed no alternative primary tumor site other than liver.
  • We propose that SCC with a grave prognosis should be considered as a rare entity of primary liver tumor even in cirrhotic patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978916.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


51. López Cubillana P, Martínez Barba E, Prieto A, Server Pastor G, Sola J, Nicolás JA, García Hernández JA, Gómez G, Martínez Pertusa P, Pérez Albacete M, Bañón V, Valdelvira P, Guardiola A, Castillo D, Cao E, Alonso JD: Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. Urol Int; 2001;67(3):209-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications.
  • One member of this group of atypical prostatic tumors is the oat-cell carcinoma, or small cell carcinoma (SCC) of the prostate.
  • At the time of diagnosis, extracapsular extension of the tumor was present in all 4 cases, with T3 or higher stages in all of them (T(3A)N(0)M(1), T(3A)N(0)M(0), T(3B)N(0)M(1), and T(4)N(0)M(0)).
  • They were all offered systemic chemotherapy with cyclophosphamide (1 g/m(2)), doxorubicin (50 mg/m(2)) and vincristine (1.2 mg/m(2)).
  • This therapeutic protocol was carried out in only 2 cases.
  • RESULTS: Survival was <1 year in the 3 patients with pure SCC, and the patient with a mixed tumor is alive with detectable disease 9 months after diagnosis.
  • CONCLUSIONS: This poor vital prognosis in SCC stresses the need for early diagnosis a timely and appropriate therapeutic intervention in this condition.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • [CommentIn] Urol Int. 2002;69(2):166-8 [12187054.001]
  • (PMID = 11598447.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


52. Burton EC, Prados MD: Malignant gliomas. Curr Treat Options Oncol; 2000 Dec;1(5):459-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are a heterogeneous group of neoplasms that comprise the majority of tumors originating in the central nervous system (CNS).
  • Tumors of mixed lineage are also seen, the most common of which is designated anaplastic oligoastrocytoma (AOA).
  • Standard treatment for these tumors is typically surgery, followed by radiation then chemotherapy.
  • Surgery is required for a definitive histopathologic diagnosis, which in turn will dictate subsequent therapy options.
  • Moreover, aggressive tumor resection improves survival outcomes, and in many cases, the patient's neurologic function.
  • We generally advocate the safest, maximal resection attainable for patients with these tumors as a way to improve prognosis.
  • In almost all cases, surgery is followed by radiation therapy.
  • Postsurgical irradiation is the most effective treatment currently available for improving survival.
  • There is also mounting evidence to suggest that additional radiation, given in the form of brachytherapy or radiosurgery, at initial diagnosis as a "boost" to standard radiation or at tumor recurrence, may provide added improvement in survival outcome.
  • Radiosurgery and brachytherapy are therapies often used to treat eligible patients at this institution.
  • Adjuvant chemotherapy, conventionally given after radiation, may offer a modest survival benefit in some patients with GBM.
  • Bischloroethylnitrosourea (BCNU) is the typical first-line agent used, but chemotherapy seems to be most beneficial in young patients, with little if any impact on survival for patients over 60 years old.
  • At this institution, we often defer treatment with adjuvant chemotherapy for elderly patients with GBM due to lack of efficacy and the attendant risk with chemotherapy.
  • For anaplastic astrocytomas, oligodendrogliomas, and oligoastrocytomas, a commonly accepted standard is adjuvant chemotherapy following irradiation with the three-drug regimen--procarbazine, CCNU, and vincristine (PCV).
  • However, recent data suggest that treatment with either PCV or BCNU may be appropriate.
  • Both regimens now appear to have equal efficacy for anaplastic gliomas in light of a more recent analysis done with larger numbers of patients.
  • AOs are a unique case with respect to tumor chemosensitivity and patient survival.
  • Molecular studies have identified a subpopulation of patients with AO whose tumors have lost chromosomes 1p and 19q.
  • Patients with this molecular pattern have an exceptional responsiveness to PCV chemotherapy and have prolonged survival.
  • Currently, trials are being conducted to confirm this finding and to determine the best treatment regimen for these patients, with particular regard to the timing of radiation and chemotherapy.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Humans. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Oct;20(9):1642-6 [10543634.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurooncol. 1999 May;42(3):233-45 [10433107.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92 [10524423.001]
  • [Cites] J Neurooncol. 1999 May;42(3):247-58 [10433108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1028-36; discussion 1036-8 [9361056.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] J Neurooncol. 1995 Nov;26(2):111-23 [8787853.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Radiology. 2000 Apr;215(1):221-8 [10751490.001]
  • [Cites] Ann Med. 2000 Feb;32(1):81-5 [10711581.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1112-20; discussion 1120-2 [10807243.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Natl Cancer Inst. 1990 Dec 19;82(24):1918-21 [2250312.001]
  • (PMID = 12057153.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09291; United States / NCI NIH HHS / CA / CA13525
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


53. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • She has been clinically free of tumor for 20 months.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bridged Compounds / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Immunoenzyme Techniques. Middle Aged. Platinum / administration & dosage. Taxoids / administration & dosage. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


54. Kim SD, Park JY, Park J, Lee JB, Kim SH, Lim DJ: Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma. Clin Neurol Neurosurg; 2007 Apr;109(3):236-41
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to compare the radiological findings before and after intratumoral bleomycin injection in patients with cystic craniopharyngioma so as to define the role of adjuvant intracavitary bleomycin chemotherapy for cystic craniopharyngiomas.
  • RESULTS: After the completion of all treatment cycles, the disappearance or shrinkage of the tumor was initially noted in all cases on follow-up CT and/or MR imaging studies.
  • However, tumor recurrence was seen in four cases with a mixed tumor type.
  • CONCLUSION: Postoperative bleomycin injection in cystic craniopharyngioma does not appear to totally eradicate the tumor and does not stop tumor recurrence unless the cyst is the only portion of the craniopharyngioma that is left.
  • Nevertheless, postoperative bleomycin injection decreases and stabilizes tumor size, and thus may be considered as an option of treatment modalities in patients with predominantly cystic craniopharyngiomas.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Craniopharyngioma. Cysts. Magnetic Resonance Imaging. Pituitary Neoplasms. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiography. Brain / surgery. Child. Combined Modality Therapy. Female. Humans. Injections. Male. Middle Aged. Neurosurgical Procedures. Postoperative Care

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046151.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


55. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors in survivors of childhood cancer.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • All patients were treated with surgical excision of the primary tumor, and postoperative radiation was added in select patients.
  • Eleven patients were alive with no evidence of disease at last follow-up, and 1 patient was alive with clinical evidence of pulmonary metastasis.
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


56. Yoney A, Eren B, Eskici S, Salman A, Unsal M: Retrospective analysis of 105 cases with uterine sarcoma. Bull Cancer; 2008 Mar;95(3):E10-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the role of adjuvant therapy in survival and to identify important prognostic factors in uterine sarcoma.
  • One hundred five patients with uterine sarcoma have been retrospectively researched to evaluate the results in this tumor group.
  • 43.8% had leiomyosarcoma, 28.6% had endometrial stromal sarcoma and 27.6% had a malign Mullarian mixed tumor while the distribution according to the histological subgroups were found to be 42.6,16.2 and 41.2% in grade I, II and III tumors respectively.
  • 38.1% of the patients had Radiotherapy, 18.1% had chemotherapy and 12.4% had chemoradiotherapy in addition to surgery.
  • The disease free survival and overall survival rates at 3rd and 5th years are 54.46, 49.88, 54.63 and 51.09% all respectively.
  • In our series, univariate analysis for overall survival demonstrated statistical significance for radical surgery, grade, stage, age, menopausal status and presence of RT in treatment modality, but; histology, number of mitosis, tumor size demonstrated no significance.
  • Our data favors treatment for uterine sarcoma with radical surgery plus radiotherapy alone over 54 Gy or with chemotherapy.
  • [MeSH-major] Leiomyosarcoma. Mixed Tumor, Mullerian. Sarcoma, Endometrial Stromal. Uterine Neoplasms
  • [MeSH-minor] Adenosarcoma / mortality. Adenosarcoma / pathology. Adenosarcoma / secondary. Adenosarcoma / therapy. Adult. Aged. Aged, 80 and over. Analysis of Variance. Bone Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390406.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


57. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S: Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer; 2007 Jan 1;120(1):196-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating BRAF(T1799A) mutation is closely associated with a papillary thyroid carcinoma (PTC) histotype.
  • The transversion is frequently detected in the conventional type, Warthin-like and tall cell variants, but is rare in the follicular variant of PTC.
  • Conventional PTC is often presented with tumors of mixed architecture, which besides the papillary structures also contain areas with follicular and solid morphology in which the details of BRAF mutational status are unknown.
  • We set out to differentially investigate the presence of mutated BRAF in the individual structural components microdissected from 44 formalin-fixed, paraffin-embedded PTC tissues from 40 patients.
  • The mutation was detected in at least 1 structural component in 23 tumors (52%).
  • Different structural components of the same tumor had identical BRAF status in 41/44 tumors (93%).
  • In 3 tumors the BRAF(T1799A) mutation was found only in the papillary, but not in the follicular component.
  • Mutational patterns identical to those in the primary tumors were found in 11/12 lymph node metastases (92%, including both BRAF(T1799A)-positive and -negative cases).
  • The high concordance of the BRAF mutational status in structurally distinct areas suggests a rather homogeneous distribution of neoplastic epithelial cells in a conventional PTC tumor in most cases.
  • These results imply the reliability of preoperative molecular diagnosis of PTC regardless of the type of tumor component at the site of biopsy sampling and suggest that the majority of patients with BRAF mutation-positive PTC may benefit from the targeted pharmacotherapy.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044028.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


58. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I: Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res; 2002 Nov;8(11):3520-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mesothelin, a cell surface glycoprotein overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas, is an attractive candidate for targeted therapy because it is not shed in significant amounts into the bloodstream and is not present in significant amounts on normal human tissues except for mesothelial cells.
  • The objective of this study was to determine the antitumor activity of SS1(dsFv)PE38, a recombinant antimesothelin immunotoxin, against human gynecologic tumors grown in short-term culture in vitro.
  • EXPERIMENTAL DESIGN: Tumor cells obtained from primary cultures of five ovarian and one cervical tumor were mixed with an equal proportion of NIH-3T3 fibroblasts and plated inside collagen gels in tissue culture plates.
  • After 4-7 days of growth, these organotypic cultures were treated with media alone, SS1(dsFv)PE38, and a control immunotoxin RFB4(dsFv)PE38, which targets the CD22 antigen not present on gynecologic tumors, every other day x 3.
  • RESULTS: Tumors expressing mesothelin showed a significant dose-dependent sensitivity to SS1(dsFv)PE38 even at concentrations as low as 1 ng/ml, whereas no antitumor activity was seen at 100 ng/ml in tumors that did not express mesothelin.
  • This activity was specifically attributable to mesothelin targeting because RFB4 (dsFv)-PE38 had no activity against mesothelin-expressing tumors.
  • CONCLUSIONS: These results demonstrate that ovarian and cervical tumor cells obtained from patients can be grown in short-term culture using an organotypic culture model.
  • Our results also show low concentrations of an immunotoxin targeting mesothelin is cytotoxic to mesothelin-expressing human tumors by inducing apoptosis.
  • [MeSH-major] Genital Neoplasms, Female / drug therapy. Immunotoxins / pharmacology. Membrane Glycoproteins / antagonists & inhibitors
  • [MeSH-minor] 3T3 Cells. Animals. Antibodies, Monoclonal. Apoptosis. Cells, Cultured. Coculture Techniques. Collagen / pharmacology. Dose-Response Relationship, Drug. Enterotoxins. Female. Fibroblasts / metabolism. GPI-Linked Proteins. Humans. Immunoglobulin Fragments / genetics. Immunoglobulin Fragments / pharmacology. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Proteins. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429643.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enterotoxins; 0 / GPI-Linked Proteins; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Membrane Glycoproteins; 0 / Proteins; 0 / SS(dsFv)PE38; 0 / SS1(dsFv)PE38; 0 / immunoglobulin Fv; 0 / mesothelin; 9007-34-5 / Collagen
  •  go-up   go-down


59. Zanetta G, Bonazzi C, Cantù M, Binidagger S, Locatelli A, Bratina G, Mangioni C: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol; 2001 Feb 15;19(4):1015-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and reproductive function after treatment of malignant germ cell ovarian tumors.
  • PURPOSE: Germ cell ovarian tumors are curable.
  • The possible sequelae of chemotherapy on long-term survivors are still unknown, but these patients may expect normal lives.
  • MATERIALS AND METHODS: Between 1982 and 1996, 169 women with malignant germ cell ovarian tumors were seen (70 dysgerminomas, 28 endodermal sinus tumors, 24 mixed tumors, and 47 immature teratomas).
  • Seventy-one had advanced or recurrent disease.
  • Fertility-sparing surgery was performed in 138 (81%) women, 81 of whom received postoperative chemotherapy.
  • RESULTS: With a median follow-up of 67 months, the survival rate was 94% for dysgerminoma, 89% for endodermal sinus tumors, 100% for mixed types, and 98% for immature teratoma.
  • Two women had adnexal recurrences, and both received salvage treatment.
  • After treatment, all but one postpubertal woman had recovery of menses within 9 months.
  • Four malformations were observed: one in 14 conceptions of patients who had not received chemotherapy and three in 41 conceptions of treated patients.
  • CONCLUSION: Irrespective of subtype and stage, conservative surgery should become the standard approach to treating most patients with malignant ovarian germ cell tumors.
  • Fertility seems to be only marginally affected by treatments.
  • The malformation rate is slightly higher than in the general population, but no significant difference was seen between patients who did and did not receive chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Congenital Abnormalities / etiology. Female. Humans. Pregnancy. Pregnancy Outcome. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11181664.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Mikuz G: [Testicular tumors. Predictive factors]. Pathologe; 2008 Nov;29 Suppl 2:270-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular tumors. Predictive factors].
  • Patients with germ cell tumors of the testis can be given adjuvant treatment immediately after orchidectomy or put under surveillance with definitive treatment deferred until relapse.
  • Both therapies are equally successful (success rate 98-99%), with surveillance alone, however, only approximately 50% of cases need toxic chemotherapy.
  • The surveillance strategy is especially successful in patients with tumors which do not have morphological predictors of metastases.
  • In seminomas the strongest predictor of metastases is tumor invasion of the rete testis followed by the size (Ø > or =4 cm) of the tumor.
  • Vascular invasion, the most important predictor in non-seminomatous germ cell tumors, is less important in seminomas.
  • The second most important predictor in mixed tumors is the presence or absence and the amount of embryonal carcinoma.
  • The presence of teratomas and yolk sac tumors are considered to be predictors of a favorable course of the disease.
  • The only reliable predictor of malignancy of the gonadal stromal tumors is the size and tumors with a diameter > or =5 cm are always malignant.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Orchiectomy. Prognosis. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ital Urol Androl. 2001 Dec;73(4):177-80 [11822063.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] Urologe A. 1999 Mar;38(2):168-78 [10231939.001]
  • [Cites] Urology. 2007 Oct;70(4):777-80 [17991554.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5482-92 [17158533.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2014-9 [12376206.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):736-40 [15708251.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):576-82 [11290432.001]
  • (PMID = 18712393.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Husain EA, Prescott RJ, Haider SA, Al-Mahmoud RW, Zelger BG, Zelger B, Al-Daraji WI: Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes. Dig Dis Sci; 2009 Feb;54(2):395-400
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to evaluate the histological features of a case series of this rare tumor and correlate these with clinical features.
  • Only primary gallbladder wall mesenchymal tumors were included.
  • Epithelial tumors, mixed tumors (carcinosarcoma or sarcomatoid carcinoma), and tumors extending into the gallbladder from the abdomen or sarcoma with other known primaries were specifically excluded.
  • RESULT: PGBS occurred in one male and six females with a median age of 70 (range 64-82) years.
  • Tumors ranged from 1.1 to 4 cm with a median size of 3 cm.
  • All tumors were associated with ulcerated mucosa.
  • Based on morphological and immunohistochemical features of the PGBS, there were three myxofibrosarcomas (malignant fibrous histiocytoma, MFH, storiform pleomorphic), one leiomyosarcoma (LMS), one angiosarcoma (AS), and two liposarcomas (LS).
  • All patients received cholecystectomy and three received adjuvant chemotherapy.
  • Follow-up revealed that six patients died of the disease 6 weeks to 2 years after diagnosis and one died of unrelated causes.
  • A variety of sarcoma types are found with MFH being the predominant variant.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):91-102 [7123848.001]
  • [Cites] Acta Chir Belg. 2004 Feb;104(1):107-9 [15053476.001]
  • [Cites] Histopathology. 1994 Mar;24(3):269-71 [7726886.001]
  • [Cites] Am J Gastroenterol. 1986 Mar;81(3):202-4 [3513545.001]
  • [Cites] Gut. 1994 Jun;35(6):854-6 [8020820.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] Rev Invest Clin. 1989 Apr-Jun;41(2):159-64 [2781178.001]
  • [Cites] Am Surg. 2001 Jul;67(7):714-7 [11450796.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1420-3 [11023105.001]
  • [Cites] Acta Oncol. 1998;37(2):212-4 [9636020.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):812-8 [7055789.001]
  • [Cites] Arch Pathol Lab Med. 2002 Apr;126(4):481-3 [11900579.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(2):225-30 [6289513.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Indian J Pathol Microbiol. 1993 Jan;36(1):78-80 [8354563.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):323-33 [6731662.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Histopathology. 1987 Feb;11(2):209-14 [2437004.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):919-27 [7260842.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1298-305 [8276377.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):609-11 [17768664.001]
  • [Cites] Ann Diagn Pathol. 1999 Apr;3(2):75-80 [10196386.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Arch Pathol Lab Med. 1995 Dec;119(12):1173-6 [7503670.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):822-5 [15985238.001]
  • [Cites] Surg Today. 2002;32(1):81-5 [11871825.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1598-604 [17895763.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]
  • [Cites] Mil Med. 1992 Oct;157(10):559-61 [1454184.001]
  • (PMID = 18618258.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, Susini C, Buscail L: Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A; 2000 Aug 1;97(16):9180-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo studies conducted in Syrian golden hamsters after orthotopic implantation of PC-1.0 cells showed that both tumor growth and metastatic progression of allografts containing 100% of sst2-expressing cells were significantly inhibited for up to 20 days after implantation, as compared with control allografts that did not express sst2.
  • A local antitumor bystander effect was observed after induction of mixed tumors containing a 1:3 ratio of sst2-expressing cells to control cells.
  • Tumor volume and incidence of metastases of mixed tumors were significantly reduced at day 13 post implantation.
  • This effect decreased with time as at day 20, growth of mixed tumors was similar to that of control tumors.
  • After administration of the cytotoxic somatostatin conjugate AN-238 on day 13, antitumor bystander effect observed in mixed tumors was significantly extended to day 20.
  • The inhibitory effect of sst2 gene expression on pancreatic cancer growth and invasion combined with chemotherapy with targeted cytotoxic somatostatin analog administration provides a rationale for a therapeutic approach to gene therapy based on in vivo sst2 gene transfer.
  • [MeSH-minor] Animals. Cadherins / metabolism. Cell Division / drug effects. Cell Division / genetics. Cell Division / physiology. Cricetinae. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Intracellular Signaling Peptides and Proteins. Male. Mesocricetus. Neoplasm Metastasis / prevention & control. Phosphorylation. Protein Phosphatase 1. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatase, Non-Receptor Type 6. Protein Tyrosine Phosphatases / metabolism. Pyrroles / administration & dosage. Tumor Cells, Cultured. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - SST2 receptor - data and references .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Jan;11(1):51-64 [10637290.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1947-53 [10213505.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2996-3001 [10850448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896-900 [2869490.001]
  • [Cites] Carcinogenesis. 1989 May;10(5):861-9 [2539915.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):557-61 [2000935.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):163-7 [1530768.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Trends Pharmacol Sci. 1995 Mar;16(3):86-8 [7792934.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1823-7 [8620499.001]
  • [Cites] Int J Pancreatol. 1996 Feb;19(1):25-30 [8656024.001]
  • [Cites] J Cell Biochem. 1996 Jun 15;61(4):524-30 [8806075.001]
  • [Cites] Digestion. 1996;57 Suppl 1:69-71 [8813474.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):956-62 [9041201.001]
  • [Cites] Hum Gene Ther. 1999 Apr 10;10(6):995-1008 [10223733.001]
  • [Cites] J Biol Chem. 1999 May 21;274(21):15186-93 [10329727.001]
  • [Cites] Eur J Endocrinol. 1999 Jul;141(1):1-14 [10407215.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):592-8 [10404076.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3771-6 [9360539.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Feb;217(2):143-52 [9452137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1794-9 [9465096.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24448-54 [9305905.001]
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Cell Adhes Commun. 1998 Jan;5(1):13-25 [9638338.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4132-7 [9751625.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):709-17 [10690557.001]
  • (PMID = 10900262.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / AN 238; 0 / Antibiotics, Antineoplastic; 0 / Cadherins; 0 / Cytotoxins; 0 / Fungal Proteins; 0 / GTPase-Activating Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Pyrroles; 0 / SST2 protein, S cerevisiae; 0 / Saccharomyces cerevisiae Proteins; 42HK56048U / Tyrosine; 80168379AG / Doxorubicin; EC 3.1.3.16 / Protein Phosphatase 1; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC16842
  •  go-up   go-down


63. Kommoss F, Kommoss S, Eichhorn J, Schmidt D: [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe; 2007 May;28(3):209-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transitional cell carcinoma of the ovary (TCC-O) is a less common type of malignant surface epithelial-stromal tumor of the ovary, still with uncertain incidence.
  • Histologically, TCC-O resembles urothelial carcinoma of the urinary system, and by definition does not contain a Brenner tumor component.
  • TCC-O may not be a bona fide urothelial neoplasm, however, but rather a lesion of the Müllerian type derived from the ovarian surface epithelium.
  • This notion is supported by the existence of mixed tumors consisting of TCC-O and other histological types of ovarian carcinoma, as well as the observation that TCC-O has a Müllerian type but not a urothelial-like immunohistochemical profile.
  • Besides metastatic urothelial carcinoma of the urinary tract, the other types of ovarian carcinoma, as well as sex cord-stromal tumors such as adult granulosa cell tumors, have to be considered in the differential diagnosis of TCC-O.
  • A recent analysis of a large series of advanced ovarian carcinomas treated by radical surgery and postoperative chemotherapy confirms studies that had suggested that TCC-O has a better prognosis (with current treatment) than that of the other histological types of ovarian carcinoma.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7 [8475964.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jul;15(3):257-65 [8811388.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1434-41 [14576476.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):839-47 [2644014.001]
  • [Cites] Am J Clin Pathol. 1998 Feb;109(2):173-80 [9583889.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):195-9 [15790458.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Virchows Arch. 2001 Feb;438(2):181-91 [11253121.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):457-65 [2321577.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1267-72 [8958296.001]
  • (PMID = 17447068.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Soumarová R, Horová H, Seneklová Z, Ruzicková J, Horová I, Budíková M, Slampa P, Kalábová R: Treatment of uterine sarcoma. A survey of 49 patients. Arch Gynecol Obstet; 2002 Apr;266(2):92-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of uterine sarcoma. A survey of 49 patients.
  • PURPOSE: Surgery, radiotherapy and chemotherapy are employed in the treatment of uterine sarcoma.
  • We claim to evaluate the role of radiotherapy in the treatment of uterine sarcoma.
  • All 49 patients had surgery, 19 (38.7%) had adjuvant radiotherapy and 25 (51%) had chemotherapy.
  • Using the FIGO classification: 71.4% had stage I, 6.1% stage II, 16.3%, stage III and 6.1% stage IVa disease.
  • 42.9% of tumors were mixed Müllerian tumors, 34.7% leiomyosarcomas and 22.4% endometrial stromal sarcomas.
  • There was an increased disease free interval (DFI) for patients treated with adjuvant radiotherapy (p = 0.005).
  • The DFI was favourably influenced by the stage of the disease.
  • Of 12 patients with a local recurrence only one had postoperative radiotherapy.
  • CONCLUSION: We conclude that postoperative radiotherapy in our series of patients diagnosed with uterine sarcoma has an impact on locoregional and disease-free progression intervals (LRFI, DFI) and overall survival (OS).
  • The most important prognostic factor is the extend of the disease (stage).

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12049303.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Brousse C, Baumelou E, Morel P: Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine; 2000;67(5):446-51
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The 28 cases of PLB, 2932 cases of ESNHL, and 219 cases of SLB included between April 1, 1993, and October 1, 1997, in a treatment protocol for NHL developed by the Adult Lymphoma Study Group, were studied prospectively.
  • The disease was monostotic in 17 cases (involving the peripheral skeleton in 14) and polyostotic in nine cases.
  • In the PLB group, 54% of patients had diffuse large cell tumors and 11% diffuse mixed tumors; in the ESNHL group, 39% had diffuse large cell, 13% diffuse mixed, and 8% diffuse immunoblastic tumors; and in the SLB group, 45% had diffuse large cell, 10% diffuse mixed, and 12% diffuse immunoblastic tumors.
  • A complete or partial response to induction therapy was noted in 86% of PLB patients, 84% of ESNHL patients, and 78% of SLB patients.
  • Further studies are needed to determine the effect of radiation therapy at completion of the treatment protocol and to look for prognostic factors associated with bone involvement.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143912.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


66. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C: Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo); 2009;64(10):961-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cutaneous tumors with topical 5% imiquimod cream.
  • INTRODUCTION: There are various approaches to the treatment of cutaneous tumors; one of them is treatment with imiquimod, a synthetic toll-like receptor agonist with a low molecular weight that offers a topical, noninvasive, and non-surgical therapeutic option.
  • The main objective of our study was to provide data on 89 patients who used a 5% imiquimod cream for the treatment of cutaneous tumors at the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas from 2003 to 2008.
  • MATERIALS AND METHODS: Here, we present our experience in the treatment of 123 cutaneous tumors of various types, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen's disease, erythroplasia of Queyrat, Paget's disease, and trichoepithelioma, with 5% imiquimod cream from 2003 to 2008 in the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas.
  • Treatment duration, response to imiquimod, follow-up, recurrence, and local and systemic reactions associated with use of the drug were analyzed.
  • Tumors were located mainly on the face, back, trunk, and legs.
  • These specific patients demonstrated cure rates of 83.5% for superficial BCC and 50% for Bowen's disease.
  • Aggressive BCC and superficial and nodular BCC did not present a good response to treatment.
  • For these patients, the cure rates were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen's disease, 50% for nodular BCC, and 50% for aggressive BCC.
  • One SCC lesion demonstrated a complete response, and tumors caused by Paget's disease and erythroplasia of Queyrat presented a partial response.
  • None of the tumors considered as clinically cured recurred.
  • Having a cutaneous comorbidity, high-risk tumors such as mixed aggressive BCC (sclerodermiform or micronodular), nodular BCC, or Bowen's disease, and presenting no local reaction to imiquimod were considered as risk factors for a worse prognosis.
  • We demonstrate that patients with no response to imiquimod, even when they demonstrated no local reaction, can undergo another cycle of six weeks of imiquimod treatment and show a complete response.
  • CONCLUSIONS: Our experience confirms imiquimod as an effective treatment option for several types of cutaneous tumors, especially in patients without the cutaneous comorbidities cited above and with low-risk tumors.
  • Imiquimod has a relatively low cost compared to other therapeutic options and can be delivered via ambulatory care to patients with surgery contraindications, and its side effects are tolerable.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Dermatol Surg. 2002 May;28(5):427-9 [12030878.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S240-8 [12271286.001]
  • [Cites] J Drugs Dermatol. 2008 May;7(5):447-51 [18505136.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1181-6 [14725659.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] J Drugs Dermatol. 2007 May;6(5):507-13 [17679185.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • (PMID = 19841702.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC2763070
  • [Keywords] NOTNLM ; Basal cell carcinoma / Imiquimod / Immunomodulator / Immunotherapy / Non-melanoma skin cancer
  •  go-up   go-down


67. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


68. Sands SA, Kellie SJ, Davidow AL, Diez B, Villablanca J, Weiner HL, Pietanza MC, Balmaceda C, Finlay JL: Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study. Neuro Oncol; 2001 07;3(3):174-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study.
  • This study evaluated the quality of life and neuropsychologic functioning among patients enrolled between 1989 and 1993 in the First International CNS Germ-Cell Tumor Study.
  • Those who received CNS radiation therapy (n = 29) reported significantly worse physical health, but similar psychosocial health, compared with those treated without radiation.
  • Those with germinomas significantly outperformed those with nongerminomatous/ mixed tumors on all neuropsychological measures administered.
  • Younger patients diagnosed with CNS germ-cell tumors are at increased risk for psychosocial and physical problems as well as neuropsychologic deficits.
  • Exposure to irradiation adversely affects overall physical functioning, whereas tumor pathology appears to be a salient neurocognitive risk factor.
  • Collaborative and randomized studies are required to further elucidate the late effects arising from factors such as age at diagnosis, tumor histology, level of irradiation therapy, and chemotherapy toxicity among these young and potentially curable patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11465398.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920620
  •  go-up   go-down


69. Louthan O: [Goblet cell carcinoid of the appendix]. Vnitr Lek; 2009 Nov;55(11):1056-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appendiceal goblet cell carcinoids are mixed tumors including neuroendocrine cells and intestinal type of goblet cells.
  • Compared to typical carcinoids, goblet cell carcinoids are malignant tumors with degree of malignity differing from case to case.
  • There is poor prognosis in larger tumors.
  • Appendectomy is a sufficient therapeutical approach in small tumors, hemicolectomy should be performed in larger ones.
  • There is limited experience with chemotherapy in metastasizing tumors and sporadic with somatostatin analogues.
  • [MeSH-major] Appendiceal Neoplasms. Carcinoid Tumor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017437.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 18
  •  go-up   go-down


70. Koletsis EN, Prokakis C, Karanikolas M, Apostolakis E, Dougenis D: Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg; 2009;4:30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Is is characterized by rapid growth and early disseminated disease with poor outcome.
  • Never the less some surgeons continue to be in favor of surgery as part of a combined modality treatment in patients with SCLC.
  • The reevaluation of the role of surgery in this group of patients is based on clinical data indicating a much better prognosis in selected patients with limited disease (T1-2, N0, M0), the high rate of local recurrence after chemoradiotherapy with surgery considered eventually more efficient in the local control of the disease and the fact that surgery is the most accurate tool to access the response to chemotherapy, identify carcinoids misdiagnosed as SCLC and treat the Non Small Cell Lung Cancer component of mixed tumors.
  • Performing surgery for local disease SCLC requires a complete preoperative assessment to exclude the presence of nodal involvement.
  • In stage I surgery must always be followed by adjuvant chemotherapy, while in stage II and III surgery must be planned only in the context of clinical trials and after a pathologic response to induction chemoradiotherapy has been confirmed.
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Humans. Neoplasm Staging. Patient Selection. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 May;6(5):832-8 [2835443.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Oct;86(4):498-506 [6312199.001]
  • [Cites] Ann Thorac Surg. 1992 Sep;54(3):498-501 [1324656.001]
  • [Cites] Chest. 1994 Dec;106(6 Suppl):320S-323S [7988254.001]
  • [Cites] Chest. 1997 Apr;111(4):1089-93 [9106591.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Nov;12(5):689-93 [9458136.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Oct;14(4):398-402 [9845145.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):64-72 [15632826.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 May;129(5):977-83 [15867769.001]
  • [Cites] Ann Thorac Surg. 2005 Aug;80(2):418-21; discussion 422 [16039176.001]
  • [Cites] Lancet. 2005 Oct 15-21;366(9494):1385-96 [16226617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):70-6 [16382115.001]
  • [Cites] Lung Cancer. 2006 Jun;52(3):263-4 [16677735.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Aug;30(2):212-6 [16829087.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2006 Fall;18(3):211-6 [17185181.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):967-71 [17720409.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):324S-339S [17873178.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):679-84 [18040612.001]
  • [Cites] J BUON. 2007 Oct-Dec;12(4):453-61 [18067202.001]
  • [Cites] J Thorac Oncol. 2008 Nov;3(11):1267-71 [18978561.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4665-72 [12488411.001]
  • [Cites] Cancer Control. 2003 Jul-Aug;10(4):289-96 [12915807.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):176-81 [14508850.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):448-56 [14710387.001]
  • [Cites] Thorac Surg Clin. 2004 May;14(2):271-81 [15382303.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Oct;26(4):782-6 [15450573.001]
  • [Cites] Am J Med. 1969 Apr;46(4):516-25 [5791000.001]
  • [Cites] Lancet. 1973 Jul 14;2(7820):63-5 [4123619.001]
  • [Cites] J Thorac Cardiovasc Surg. 1982 Oct;84(4):481-8 [6289013.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Mar;101(3):385-93 [1847981.001]
  • (PMID = 19589150.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2716318
  •  go-up   go-down


71. Bernardini FP, Devoto MH, Croxatto JO: Epithelial tumors of the lacrimal gland: an update. Curr Opin Ophthalmol; 2008 Sep;19(5):409-13
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial tumors of the lacrimal gland: an update.
  • PURPOSE OF REVIEW: The goal of this article is to offer an update on the treatment and prognosis of the most common epithelial tumors of the lacrimal gland, report on new pathological entities and offer a review of the classification of lacrimal gland tumors.
  • RECENT FINDINGS: Improvements have been made in the understanding of lacrimal gland lesions with the knowledge that lacrimal gland tumors compare to the more common counterparts of the major salivary glands.
  • Therefore, the WHO's classification of salivary gland tumors has been adapted to the lacrimal gland pathology.
  • Until recently, primary adenocarcinomas of the lacrimal gland were not further subclassified, but they can now be divided into low-grade and high-grade malignancies.
  • The adjunctive use of intra-arterial cytoreductive chemotherapy for the management of adenoid cystic carcinoma is one of the most important advancements on the management of these aggressive tumors.
  • Another important step forward has been taken on carcinoma ex pleomorphic adenoma of the lacrimal gland, which is subclassified into noninvasive carcinoma, with an excellent prognosis after complete excision and invasive carcinoma for which the prognosis is still guarded despite adjunctive radiotherapy.
  • SUMMARY: This article offers an update on diagnosis, classification and treatment of common and rare epithelial lacrimal gland tumors.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772674.001).
  • [ISSN] 1531-7021
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


72. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C: Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer; 2004 Apr 15;100(8):1712-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
  • The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG.
  • METHODS: Eligibility criteria included histologically confirmed newly diagnosed AG with measurable enhancing disease, a Karnofsky performance score (KPS) > or = 60, normal pulmonary function, and normal laboratory parameters.
  • BCNU given at a dose of 150 mg/m(2) intravenously was followed after 2 hours by TMZ given at a dose of 550 mg/m(2) orally on Day 1 of a 42-day cycle to a maximum of 4 cycles, unless there was tumor progression or unacceptable toxicity.
  • The histology was 81% anaplastic astrocytoma, 12% anaplastic oligodendroglioma, and 7% mixed tumors.
  • Two patients died while receiving therapy, 1 of progressive disease and the other of Pneumocystis carinii pneumonia.
  • An additional 54% of patients had stable disease.
  • Seventeen percent developed progressive disease (10% after the first cycle and 7% after the second cycle).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15073861.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62405; United States / NCI NIH HHS / CA / CA62407; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62421; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR03186
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


73. Craighead PS, Sait K, Stuart GC, Arthur K, Nation J, Duggan M, Guo D: Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol; 2000 May;77(2):248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to determine the patient characteristics and outcome of patients with aggressive histologic variants (AV) of endometrial carcinoma, including uterine papillary serous carcinoma (UPSC), uterine clear cell carcinoma (UCCC), and mixed type.
  • METHODS AND MATERIALS: All cases with AV histological type of endometrial carcinoma from January 1984 to December 1994 at the Tom Baker Cancer Centre were identified using the Alberta Cancer Registry.
  • Relevant data from the charts of these patients were entered into a study database (Microsoft Excel) and analyzed for presentation, demography, treatment parameters, and outcome of treatment.
  • All pathology was reviewed at the time of diagnosis.
  • Statistical analysis was performed using the S-plus statistics computer program.
  • RESULTS: A total of 103 patients with AV histological type were identified and analyzed; there were 61, 31, and 11 cases of UPSC, CCC, and mixed tumors, respectively.
  • Sixty-three patients had Stage I, 11 had Stage II, 15 had Stage III, and 14 had Stage IV disease.
  • The median age of patients was 67 years with a range of 36 to 86 years.
  • Median follow-up was 60 months with a range of 36 to 156 months.
  • Forty six percent of all cases underwent surgery alone, 39% underwent treatment which included pelvic RT, and 17% underwent treatment which included chemotherapy.
  • Chemotherapy improved overall survival, but made little difference in distant relapse rates.
  • CONCLUSIONS: Stage Ia cases treated by surgery alone have a low risk of relapse and need not be offered adjuvant systemic therapy or pelvic radiation.
  • Systemic therapy did not significantly improve distant relapse-free survival, but did extend overall survival.
  • Stage IV patients usually died within 6 months with a few responding to systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Carcinoma, Papillary / therapy. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Demography. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10785473.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


74. Huang X, Zhang R, Zhou LF: [Grading system for diagnosis and treatment of intracranial nongerminomatous malignant germ cell tumors]. Zhonghua Yi Xue Za Zhi; 2009 Sep 8;89(33):2333-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Grading system for diagnosis and treatment of intracranial nongerminomatous malignant germ cell tumors].
  • OBJECTIVE: To discuss the clinical feature, treatment and prognosis of intracranial nongerminomatous malignant germ cell tumors (NGMGCT).
  • METHODS: The records of 39 patients receiving treatment at our hospital between 1995 and 2007 were reviewed retrospectively.
  • According to the classification of Matsutani, they were grouped into intermediate prognosis and poor prognosis groups based on tumor histology.
  • Clinical manifestations, diagnosis, treatment and outcome were analyzed in each group.
  • RESULTS: In these 39 cases, there were 15 mix germ cell tumors, 15 immature teratomas, 7 embryonal carcinomas and 2 yolk sac tumors.
  • The tumor was totally removed in 29 cases, sub-totally in 5 and partially in 3.
  • Embryonal carcinoma can be classified to the intermediate prognosis group because of its similar prognosis with immature teratoma and mixed tumors composed mainly of germinoma or teratoma.
  • Surgery remains the first choice for NGMGCT since treatment should be based on tumor histology.
  • For patients in the intermediate prognosis group, a combined regimen of surgical resection, radiotherapy, chemotherapy and gamma knife surgery is mostly effective.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095355.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • The tumors were right-sided in 35, left-sided in 28, and bilateral in 3.
  • Sixteen patients had an emergency operation for tumor torsion.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Histologically, teratomas were found most frequently (mature: 45, immature: 9), followed by mixed tumors (n = 7), yolk sac tumors (n = 3), dysgerminoma (n = 2), gonadoblastoma (n = 2), and embryonal carcinoma (n = 1).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • Two patients, with malignant disease, died.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


76. Sunyach MP, Pommier P, Martel Lafay I, Guyotat J, Ginestet G, Jouanneau E, Jouvet A, Sindou M, Bret P, Carrie C, Frappaz D: Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):296-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
  • PURPOSE: To assess whether conformal radiotherapy (CRT) after incomplete surgery or biopsy for pure oligodendrogliomas and mixed gliomas results in decreased long-term sequelae without impairing local control and while reducing irradiated volume.
  • MATERIALS AND METHODS: Twenty-six consecutive patients who presented with pure (21) or mixed (5) oligodendrogliomas and who were given incomplete resections were treated according 3 different strategies: CRT alone (12), chemotherapy followed by CRT (4), and chemotherapy and delayed CRT at the time of tumor progression (10).
  • Median dose was 60 Gy.
  • Quality of CRT was assessed using tumor and normal tissue conformal indexes.
  • Among 11 nonevolutive patients, 6 have a full-time or part-time job.
  • CONCLUSIONS: Despite CRT, infield recurrence was a common feature in patients with oligodendrogliomas and mixed tumors.
  • Further research, including molecular biology typing of tumors and type of treatment, is warranted to improve survival and quality of life.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Damage, Chronic / etiology. Brain Injuries / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Employment. Female. France / epidemiology. Humans. Life Tables. Lomustine. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Procarbazine. Psychological Tests. Quality of Life. Radiotherapy Dosage. Radiotherapy, Adjuvant. Social Adjustment. Surveys and Questionnaires. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694851.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  • [Number-of-references] 44
  •  go-up   go-down


77. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • Treatment was known in 50 patients: 10 had polypectomy, 1 cone biopsy, and 39 hysterectomy, which was accompanied by bilateral salpingo-oophorectomy in 24 and lymphadenectomy in 4.
  • Five patients had radiotherapy and 2 of them had chemotherapy.
  • Of 30 tumors of the uterine corpus, 17 were stage IA, 11 stage IB, 1 stage IC, and 1 stage IIIC.
  • Four cervical tumors were stage IB.
  • Three of the 4 ovarian tumors were stage IA and the other was stage IIIC.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Most uterine tumors were polypoid masses ranging from 1 to 20 cm (mean: 6.5 cm).
  • Fourteen of 30 uterine tumors (47%) had myometrial invasion that was minimal in 5, involved one-third of the myometrial thickness in 7, and more than 50% in 2.
  • Of 4 cervical tumors, 2 were endocervical polyps, 1 invaded one-third of the cervical wall, and the other invaded its full thickness.
  • Six developed metastases and 5 of them died of tumor.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • These findings suggest that some of the tumors currently classified as adenofibromas, on the basis of their low mitotic count and lack of significant nuclear atypia, are, in fact, well-differentiated adenosarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Valdevenito Sepúlveda JP, Merhe Nieva E, Valdevenito Sepúlveda R, Cuevas Toro M, Gómez Gallo A, Bermúdez Luna H, Contreras Meléndez L, Gallegos Méndez I, Gallardo Escobar J, Palma Ceppi C: [Reduced retroperitoneal lymphadenectomy for clinical stage I non seminomatous germ cell testicular cancer]. Arch Esp Urol; 2007 Apr;60(3):245-54
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Linfadenectomia retroperitoneal reducida en cancer testicular de celulas germinales no seminomatoso estadio clinico I.
  • OBJECTIVES: The best treatment of clinical stage I non-seminomatous germ cell testicular cancer (NSGCTC) is controversial.
  • The objective of this study is to analyse our experience in the treatment of this patients with radical orchiectomy and reduced retroperitoneal lymphadenectomy (RRL) as the initial treatment.
  • INCLUSION CRITERIA: retroperitoneal staging with computed tomography (CT), normal tumor markers after orchiectomy and testicular and retroperitoneal biopsy informed at our hospital.
  • RESULTS: 36 patients with 37 testicular tumors were analysed (1 bilateral case).
  • Twenty nine mixed tumors (78%); most frequent histology embryonal carcinoma (76%).
  • Average surgery time 2 hr 7 min; average dissected lymph nodes 13.
  • Chemotherapy in 7 patients (19%) a total of 18 cycles.
  • Four cases of contralateral tumor during follow-up (11%).

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601299.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP: Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer; 2004 May 4;90(9):1720-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better define its clinicopathological features, the records of all patients with this disease seen at Memorial Sloan Kettering Cancer Center between 1980 and 2002 (n=64) were reviewed.
  • The most common primary tumour locations were in the large bowel and oesophagus.
  • In all, 37% had mixed tumour histology and 48% presented with extensive disease, according to the Veterans' Administration Lung Study group (VALSG) staging system used for small-cell lung cancer.
  • Treatment outcome in limited disease (LD) suggested a role for surgery and chemotherapy.
  • The 2-year survival was 23% and two prognostic factors were identified, the extent of disease according to the VALSG system (P<0.01) and TNM stage (P=0.03).
  • Mixed tumour histology is common and may affect therapy.
  • Surgery, combined with chemotherapy, should be considered for LD.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):262-7 [10640955.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):458-61 [9781599.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):523-33 [10931451.001]
  • [Cites] Am J Clin Oncol. 2000 Oct;23(5):455-9 [11039503.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):595-601 [11342770.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Sep;28(9):1283-6 [11579641.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1321-5 [11697847.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1184-97 [12218575.001]
  • [Cites] Clin Colorectal Cancer. 2001 Aug;1(2):87-94 [12445366.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):31-42 [4580860.001]
  • [Cites] Am J Gastroenterol. 1974 Jun;61(6):481-3 [4366115.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):515-9 [10027322.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):216-21 [10029452.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):889-91 [13000600.001]
  • [Cites] Hum Pathol. 1977 Jul;8(4):433-40 [892795.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1558-61 [7189441.001]
  • [Cites] Am J Epidemiol. 1980 Apr;111(4):444-52 [7377187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):147-52 [6321409.001]
  • [Cites] Hum Pathol. 1984 May;15(5):460-8 [6327495.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1645-61 [6089995.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):9-21 [2434408.001]
  • [Cites] Am J Gastroenterol. 1987 Apr;82(4):382-5 [3031980.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1531-3 [2550125.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):422-4 [1688727.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Am J Gastroenterol. 1991 Sep;86(9):1167-75 [1715667.001]
  • [Cites] Eur J Cancer. 1992;29A(1):81-6 [1332739.001]
  • [Cites] Pathology. 1993 Jul;25(3):240-2 [8265240.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Feb;109(2):284-8 [7531797.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Rev Esp Enferm Dig. 1996 Aug;88(8):533-8 [8962757.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):130-4 [9047250.001]
  • [Cites] Acta Oncol. 1997;36(1):78-80 [9090972.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):110-3 [9726102.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):228-33 [10656731.001]
  • (PMID = 15150595.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409752
  •  go-up   go-down


80. Wasko R, Sawicka J, Stachowiak C, Kozak W, Junik R, Sowinski J: [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors]. Ann Endocrinol (Paris); 2002 Dec;63(6 Pt 1):532-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
  • [Transliterated title] Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes.
  • Acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of GH or IGF-1.
  • About 15% of tumors secrete not only GH but PRL as well.
  • Last time a lanreotide and an octreotide (the somatostatine analogues) are useful in the therapy of acromegaly.
  • We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors.
  • [MeSH-major] Acromegaly / etiology. Antineoplastic Agents / therapeutic use. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / blood. Pituitary Neoplasms / drug therapy. Prolactin / blood. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Growth Hormone / secretion. Human Growth Hormone / blood. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527855.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


81. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year.
  • The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4).
  • Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • Surgical radicality was achieved in 76% and radicality was unrelated to tumour histology.
  • No significant difference was observed in 5-year crude survival or in the post-operative facial nerve function between the radically operated patients (n = 38) and patients with residual tumour (p = 0.27, Log-rank test), (p = 0.48, chi 2 test).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


82. Bommakanti K, Panigrahi M, Yarlagadda R, Sundaram C, Uppin MS, Purohit AK: Optic chiasmatic-hypothalamic gliomas: is tissue diagnosis essential? Neurol India; 2010 Nov-Dec;58(6):833-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic chiasmatic-hypothalamic gliomas: is tissue diagnosis essential?
  • The advocated treatment is mainly primary radiotherapy without a histological diagnosis.
  • They were grouped into three groups on the basis of radiological features and treated with a suspected diagnosis.
  • RESULTS: The three radiological groups were: Group-1 solid tumors with or without microcysts in 9 patients (histology: 8 pilocystic astrocytomas and 1 tuberculoma); Group-2 mixed tumors with solid and cystic components in 9 patients (histology: 7 pilocytic astrocytomas and 2 craniopharyngiomas); Group-3 ring enhancing lesions in 6 patients (all the 6 patients initially received antituberculous treatment, in 3 patients the lesion resolved and in the remaining 3 patients the lesion was subjected to biopsy as it did not resolve, the biopsy was suggestive of pilocytic astrocytoma).
  • Biopsy and tissue diagnosis should always be sought before instituting radiotherapy or chemotherapy for optic chiasmatic-hypothalamic gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurol India. 2011 Jan-Feb;59(1):144 [21339694.001]
  • (PMID = 21150045.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


83. Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, Mandahl N, Borg A, Widegren B, Salford LG: Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol; 2007 Oct;85(1):11-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are among the most aggressive malignant tumors and the most refractory to therapy, in part due to the propensity for malignant cells to disseminate diffusely throughout the brain.
  • Here, we have used 27 K cDNA microarrays to investigate global gene expression changes between normal brain and high-grade glioma (glioblastoma multiforme) to try and better understand gliomagenesis and to identify new therapeutic targets.
  • We have also included smaller groups of grade II and grade III tumors of mixed astrocytic and oligodendroglial origin as comparison.
  • We developed a novel algorithm to analyze the gene expression data from the perspective of chromosomal position, and identified distinct regions of the genome that displayed coordinated expression patterns that correlated significantly to tumor grade.
  • Furthermore, to enrich for more suitable targets for therapy, we took a bioinformatics approach and annotated our signatures with two published datasets that identified membrane/secreted genes from cytosolic genes.
  • Software for the chromosome analysis was developed and is freely available at http://base.thep.lu.se.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Chromosomes / genetics. Chromosomes / ultrastructure. Genes, Neoplasm / genetics. Glioma / genetics. Glioma / therapy. Immunotherapy
  • [MeSH-minor] Algorithms. Biomarkers, Tumor. Cluster Analysis. DNA, Complementary / biosynthesis. DNA, Complementary / genetics. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Drug Delivery Systems. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / physiology. Humans. In Situ Hybridization. Models, Statistical. Oligonucleotide Array Sequence Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4272-81 [15452186.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):27-35 [14649883.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):1920-32 [16127175.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):506-9 [3418382.001]
  • [Cites] Oncogene. 2001 Feb 1;20(5):609-18 [11313993.001]
  • [Cites] Clin Exp Metastasis. 1999 May;17(3):221-30 [10432007.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 15;5:151 [15488149.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8682-7 [15574777.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Methods Mol Med. 2002;68:205-22 [11901504.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404 [8816812.001]
  • [Cites] J Physiol. 2000 Dec 15;529 Pt 3:541-52 [11195932.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):405-11 [3335011.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5009-13 [9823299.001]
  • [Cites] Bioinformatics. 2004 Sep 22;20(14):2305-6 [14962935.001]
  • [Cites] J Reprod Immunol. 2004 Jun;62(1-2):19-27 [15288178.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2112-3 [15572464.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):811-6 [14533014.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6967-79 [15273741.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Nat Genet. 2000 May;25(1):58-62 [10802657.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2993-8 [12036902.001]
  • [Cites] Bioinformatics. 2000 Nov;16(11):1038-9 [11159315.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):153-7 [16454553.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Genomics. 2005 Mar;85(3):401-12 [15718107.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10573-81 [8387522.001]
  • [Cites] Onkologie. 2004 Oct;27(5):487-91 [15585981.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12 ):880-7 [15956649.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3533-43 [15284100.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5546-51 [2901288.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):523-8 [15977644.001]
  • (PMID = 17634744.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082783-07; United States / NCI NIH HHS / CA / R01 CA082783-06; United States / NCI NIH HHS / CA / CA082783; United States / NCI NIH HHS / CA / R01 CA082783; United States / NIGMS NIH HHS / GM / 5T32 GM07367
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / DNA, Neoplasm
  •  go-up   go-down


84. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • Five patients had a local recurrence after surgery; of those patients, two had initially presented with recurrent tumors.
  • Local tumors recurred as late as 15 years after the initial surgery.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • The most common initial diagnoses were polymorphous low-grade adenocarcinoma, adenoid cystic carcinoma, and pleomorphic adenoma.
  • CONCLUSIONS: Polymorphous low-grade adenocarcinoma is an increasingly recognized malignancy that originates predominantly in the minor salivary gland.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


85. Chen ZX, Zhang Q, Guo ZM, Wei MW, Yang AK: [Clinical analysis of salivary malignant pleomorphic adenoma--a report of 95 cases]. Ai Zheng; 2006 Sep;25(9):1144-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of salivary malignant pleomorphic adenoma--a report of 95 cases].
  • BACKGROUND & OBJECTIVE: Malignant pleomorphic adenoma is rare with extensive location, which makes it difficult to evaluate the efficacy of the treatments.
  • This study was to summarize the clinical features of salivary malignant pleomorphic adenoma, and thus to explore the treatment principle and efficacy of the treatment.
  • METHODS: Clinical data of 95 salivary malignant pleomorphic adenoma patients, treated in Cancer Center, Sun Yat-sen University from May 1970 to Oct.
  • The 5-and 10-year disease-specific survival rates for the patients received surgery (51 cases), surgery plus radiotherapy (35 cases) were 76.1%, 63.7% and 69.9%, 50.8%, respectively, but the 5-and 10-year disease-specific survival rates for the patients received radiotherapy only, chemotherapy only and radiochemotherapy (4 cases) were all 0.
  • CONCLUSIONS: Surgery or surgery-dominated multi-modality are the principal treatment modalities for salivary malignant pleomorphic adenoma.
  • The efficacy of surgery and surgery plus radiotherapy is better than non-surgery treatments.
  • [MeSH-major] Adenoma, Pleomorphic / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Parotid Neoplasms / therapy. Retrospective Studies. Submandibular Gland Neoplasms / therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965659.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Deschamps L, Dokmak S, Guedj N, Ruszniewski P, Sauvanet A, Couvelard A: Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature. JOP; 2010;11(1):64-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature.
  • CONTEXT: Mixed endocrine tumors are double neoplasms with both glandular and endocrine components; these tumors are rare, especially those arising in the ampulla of Vater.
  • Ampullary somatostatinomas are classically associated with neurofibromatosis type 1.
  • We herein describe the first reported case of a mixed endocrine somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1; we also present a review of the literature of the 7 mixed endocrine tumors of the ampulla which have been reported so far.
  • Endoscopic examination revealed a tumor involving the ampulla of Vater and a CT scan identified stenoses of both the distal common bile duct and the main pancreatic duct.
  • A pancreaticoduodenectomy was performed and pathological examination revealed two tumor components, exocrine (high grade adenoma with infiltrative adenocarcinoma) and endocrine (expressing somatostatin hormone) with lymph node metastases originating from both types.
  • The patient was treated with adjuvant chemotherapy and has had no recurrence for 3 years.
  • DISCUSSION: In ampullary somatostatinomas, psammoma bodies are pathognomonic and chromogranin A is rarely expressed: these features should alert the pathologist to an association with neurofibromatosis type 1.
  • The management of patients with mixed tumors is challenging.
  • The treatment of choice is surgery, and adjuvant chemotherapy should be adapted to the most aggressive component, i.e. the exocrine one.
  • CONCLUSION: Because of their rarity, the diagnosis of ampullary mixed endocrine tumors is difficult.
  • Our case points out the characteristic features of these neoplasms and their possible association with neurofibromatosis type 1.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / diagnosis. Mixed Tumor, Malignant / diagnosis. Neurofibromatosis 1 / diagnosis. Somatostatinoma / diagnosis


87. Gütgemann I, Lehman NL, Jackson PK, Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol; 2008 Apr;21(4):445-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for its resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis.
  • We investigated Emi1 protein expression in ovarian neoplasms using a tissue microarray constructed from 339 primary ovarian surface epithelial (serous, endometrioid, clear cell, and mucinous) and peritoneal (serous) neoplasms, stromal and mesenchymal tumors, germ cell tumors, and normal ovarian tissue.
  • Significant overexpression of Emi1 protein was present in 82% (27/33) clear cell carcinoma, including one borderline tumor in a diffuse, granular cytoplasmic and perinuclear staining pattern, independent of patient age, presence of ovarian and/or pelvic endometriosis, and FIGO stage.
  • Emi1 protein expression was present in mixed endometrioid/clear cell tumors but absent in tumors with mixed serous/clear cell histology.
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cyclin E / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Receptors, Estrogen / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204430.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


88. Sredni ST, Gadd S, Huang CC, Breslow N, Grundy P, Green DM, Dome JS, Shamberger RC, Beckwith JB, Perlman EJ, Renal Tumor Committee of the Children's Oncology Group: Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res; 2009 Nov 15;15(22):6800-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
  • PURPOSE: Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy.
  • The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy.
  • Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors.
  • Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR.
  • One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition.
  • The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1.
  • Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses.

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):260-7 [9781905.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3972-7 [9108089.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):1943-53 [15579438.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2592-601 [15805255.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):997-1007 [15746151.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7434-43 [16243817.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jun;46(7):728-38 [16425275.001]
  • [Cites] Genetics. 2006 Jul;173(3):1547-53 [16702428.001]
  • [Cites] EMBO J. 2006 Nov 1;25(21):5214-28 [17036046.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):765-74 [17332914.001]
  • [Cites] Curr Pharm Des. 2007;13(7):671-86 [17346183.001]
  • [Cites] Development. 2007 Sep;134(17):3177-90 [17693601.001]
  • [Cites] Nature. 2008 Jan 31;451(7178):583-6 [18235501.001]
  • [Cites] Arch Physiol Biochem. 2008 Feb;114(1):23-37 [18465356.001]
  • [Cites] Dev Cell. 2008 Nov;15(5):781-91 [19000842.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1770-8 [19208794.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3719-24 [11533093.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2181-90 [12057921.001]
  • [Cites] J Endocrinol. 2003 Aug;178(2):177-93 [12904166.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1588-604 [14531791.001]
  • [Cites] Cancer. 1979 Jul;44(1):52-7 [222434.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):1-36 [2156243.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):91-5 [8380295.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):205-12 [8383281.001]
  • [Cites] Kidney Int. 1994 Oct;46(4):1031-42 [7532247.001]
  • [Cites] EMBO J. 1995 Oct 2;14(19):4662-75 [7588596.001]
  • [Cites] Med Pediatr Oncol. 1996 Nov;27(5):422-8 [8827069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • (PMID = 19903788.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA088131-06; United States / NCI NIH HHS / CA / U10CA98543; United States / NCI NIH HHS / CA / CA088131-06; United States / NCI NIH HHS / CA / U10CA42326; United States / NCI NIH HHS / CA / CA042326-18; United States / NCI NIH HHS / CA / U01 CA088131; United States / NCI NIH HHS / CA / R01 CA054498; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA042326-18; None / None / / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA042326; United States / NCI NIH HHS / CA / UO1CA88131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  • [Other-IDs] NLM/ NIHMS140310; NLM/ PMC2782600
  •  go-up   go-down


89. Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F, Partensky C: Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas; 2008 Nov;37(4):352-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with intraductal-papillary-mucinous-neoplasia, cystadenocarcinoma, acinous-adenocarcinoma, neuroendocrine, or mixed tumors were excluded.
  • Median tumor size was 30 mm.
  • Tumors were pT2 (n = 1), pT3 (n = 24), pT4 (n = 5), 12 N+, 1 M+.
  • Twenty patients had adjuvant radiotherapy, and 18 had concomitant chemotherapy.
  • Nineteen patients are alive, 1 with recurrence and 18 with no evidence of disease (2 had more than 20 years of follow-up).
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. France / epidemiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pancreas. 2008 Nov;37(4):349-51 [18953246.001]
  • (PMID = 18665012.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


90. Butte JM, Torres J, Duarte I, Zúñiga A: [Composite tumor of the colon with liver metastases]. Cir Esp; 2007 Aug;82(2):128-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Composite tumor of the colon with liver metastases].
  • [Transliterated title] Tumor mixto del colon con metástasis hepáticas.
  • Colonic composite tumors are uncommon masses composed of endo- and exocrine cells.
  • Treatment is similar to that of adenocarcinomas.
  • We report the case of a 44-year-old woman who consulted for abdominal pain.
  • A computed tomography (CT) scan showed a tumor at the splenic flexure bowel and 2 hepatic nodules, suggesting metastases.
  • Extended right colectomy was performed, followed by an ileal-sigmoid anastomosis, resection of a diaphragm segment, and resection of both hepatic metastases.
  • Histological analysis showed moderately differentiated tubular adenocarcinoma combined with a poorly differentiated neuroendocrine carcinoma and metastases in 25 of 28 lymph nodes.
  • The patient is currently asymptomatic and is undergoing chemotherapy.
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785149.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


91. Nouraei SA, Ferguson MS, Clarke PM, Sandison A, Sandhu GS, Michaels L, Rhys-Evans P: Metastasizing pleomorphic salivary adenoma. Arch Otolaryngol Head Neck Surg; 2006 Jul;132(7):788-93
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing pleomorphic salivary adenoma.
  • OBJECTIVE: To address questions about the etiology, behavior, optimal treatment, and prognosis of metastasizing pleomorphic adenoma (MPA), we undertook a review of the literature (1953-2005) and constructed a virtual series of all identified cases of MPA, metastatic lesions that are very occasionally identified in patients with a history of pleomorphic salivary adenoma and, on detailed pathological evaluation, found to exhibit all the histological hallmarks of the preceding benign lesions.
  • There was an overwhelming history of incomplete surgery for pleomorphic salivary adenoma.
  • There was significant morbidity and mortality from distant disease, with 5-year disease-specific and disease-free survival of 58% and 50%, respectively.
  • Developing distant lesions within 10 years of the primary tumor and presence of metastases in multiple sites were independent predictors of survival on Cox regression analysis.
  • Metastasectomy conferred significant survival advantage over nonoperative treatment (log-rank analysis, P<.02).
  • Chemotherapy and radiotherapy were of limited value.
  • Metastatic disease carries significant morbidity and mortality and should be treated surgically when feasible.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847191.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


92. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC: Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer; 2006 Apr 1;106(7):1617-23
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
  • BACKGROUND: The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy.
  • Before imatinib, Bcl-2 expression in GIST was associated with a worse prognosis or added no additional prognostic value.
  • To the authors' knowledge, the current study is the first to evaluate Bcl-2 expression in pre-imatinib GIST tissue samples as a prognostic marker of progression-free survival (PFS) time in patients treated with imatinib.
  • RESULTS: Sixty-one (75%) patients had tumors that expressed Bcl-2, and 20 (25%) patients had tumors that were negative for Bcl-2.
  • All epithelioid tumors (n = 12) expressed Bcl-2 and tumors with mixed morphology exhibited Bcl-2 expression in the epithelioid component.
  • A trend toward longer PFS for patients whose tumors expressed Bcl-2 at a greater immunohistochemical intensity was observed (20.6 mos for no Bcl-2 expression; 28.3 mos for 1++Bcl-2 expression; 31.9 mos for 1.5++Bcl-2 expression; 40.8 mos for 2++Bcl-2 expresssion; and 35.9 mos for 3++Bcl-2 expression).
  • Larger studies may help elucidate the influence of Bcl-2 expression on PFS after therapy with imatinib.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / genetics. Piperazines / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Disease Progression. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518826.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K23CA109060-01; United States / NCI NIH HHS / CA / R01 CA098570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


93. Bermúdez A, Vighi S, García A, Sardi J: Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol Oncol; 2001 Jul;82(1):32-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge.
  • OBJECTIVE: The aim of this study was to analyze diagnostic criteria, response to chemotherapy, rate and site of relapse, and overall survival (OS) in neuroendocrine cervical carcinoma.
  • Patients with stage Ib(2) or greater received neoadjuvant chemotherapy (NCH).
  • Tumor was pure in 12 cases.
  • Tumors <4 cm had no recurrences.
  • Pure tumors >4 cm had distant relapses (6/11).
  • Mixed tumors >4 cm had 2/6 pelvic and 3/6 lung metastases. OS was 39%.
  • When the initial tumor volume was <4 cm OS was 76%, and it was 18% for tumors >4 cm (P < 0.05).
  • OS was 58% when the residual tumor after NCH was <2 cm and 21% when it was >2 cm (P < 0.05).
  • When the tumor was pure OS was 54% and 19% when it was mixed (P < 0.05).
  • (3) The pattern of relapse differs for mixed tumors;.
  • (4) For tumors <4 cm outcome is similar to that of squamous carcinoma.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / drug therapy. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Female. General Surgery. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11426959.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Kyritsis AP: Management of primary intracranial germ cell tumors. J Neurooncol; 2010 Jan;96(2):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary intracranial germ cell tumors.
  • Primary intracranial germ cell tumors are rare and usually localized in the pineal and the suprasellar regions.
  • They are divided into the following histologic types: germinoma, teratoma (mature, immature, malignant), choriocarcinoma, embryonal carcinoma, endodermal sinus tumor (yolk sac tumor), and mixed tumors.
  • Localized germinomas are treated with radiation therapy and exhibit a relatively good prognosis.
  • Chemotherapy is reserved for disseminated germinomas.
  • The rest of germ cell tumors are managed with various combinations of surgery, chemotherapy, and radiotherapy depending on the tumor type.
  • If the tumors secrete beta-human chorionic gonadotrophin (hCG) or alpha-fetoprotein (FP), these tumor markers can be used to accurately monitor response to treatment.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / classification. Neoplasms, Germ Cell and Embryonal / therapy. Pinealoma / therapy
  • [MeSH-minor] Carcinoma, Embryonal / therapy. Germinoma / therapy. Humans. Magnetic Resonance Imaging / methods. Nerve Tissue Proteins / metabolism. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):231-4 [7534740.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Sep;38(9):574-7 [9805904.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):518-22; discussion 522-3 [11270541.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):162-5 [11504371.001]
  • [Cites] Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1166-71 [17425677.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):177-83 [12134909.001]
  • [Cites] Oncologist. 2008 Jun;13(6):690-9 [18586924.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):503-6 [8862714.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):571-4 [9870692.001]
  • [Cites] J Neurooncol. 2007 Jun;83(2):199-204 [17205387.001]
  • [Cites] Radiographics. 1992 May;12 (3):577-96 [1609147.001]
  • [Cites] Neuroradiology. 2002 May;44(5):382-8 [12012121.001]
  • [Cites] Arch Gynecol Obstet. 2004 Jan;269(2):159-60 [14648186.001]
  • [Cites] J Neurol. 1998 Sep;245(9):593-7 [9758297.001]
  • [Cites] J Neurooncol. 1994;19(3):217-26 [7807172.001]
  • [Cites] J Neurosurg. 2008 May;108(5):1014-7 [18447721.001]
  • [Cites] Curr Treat Options Oncol. 2006 Nov;7(6):505-16 [17032562.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17763-8 [16306258.001]
  • [Cites] AJR Am J Roentgenol. 1989 Dec;153(6):1269-74 [2554702.001]
  • [Cites] J Neurosurg. 2003 Jul;99(1):106-14 [12854751.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e2 [17140183.001]
  • [Cites] Surg Neurol. 2000 May;53(5):432-7; discussion 437-8 [10874141.001]
  • [Cites] Genomics. 2003 Jan;81(1):15-25 [12573257.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):225-40 [15015791.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):900-3 [2472471.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):676-83 [15497121.001]
  • [Cites] Acta Neurochir (Wien). 1987;86(1-2):33-41 [2441574.001]
  • [Cites] AJR Am J Roentgenol. 1990 Jul;155(1):143-51 [2162137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):511-8 [12738328.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Cancer Treat Rev. 2000 Aug;26(4):233-42 [10913379.001]
  • [Cites] Surg Neurol. 2003 Apr;59(4):250-68 [12748006.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jun;61(6):531-8 [12071636.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):293-5 [8600345.001]
  • (PMID = 19588227.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  • [Number-of-references] 42
  •  go-up   go-down


95. Bradley P, McClelland L, Mehta D: Paediatric salivary gland epithelial neoplasms. ORL J Otorhinolaryngol Relat Spec; 2007;69(3):137-45
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric salivary gland epithelial neoplasms.
  • Salivary gland epithelial neoplasms in children are rare.
  • Surgery is the primary treatment of choice in the majority of cases, with the addition of adjuvant radiotherapy +/- chemotherapy when the diagnosis is a high-grade tumour and/or when the malignancy presents as a large mass or is associated with local tissue invasion.
  • Minor salivary gland neoplasms also present, the oral cavity is most frequent, with pleomorphic adenoma and mucoepidermoid carcinoma being most common, other malignant neoplasms have been reported in other sites.
  • [MeSH-major] Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17264529.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 46
  •  go-up   go-down


96. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • Perineural spread was histologically found in all cases of malignant disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


97. Schmidt D: [Endometrial carcinomas and precursor lesions--new aspects]. Pathologe; 2009 Jul;30(4):261-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinomas can be separated into two groups which are designated as type I and type II carcinomas today.
  • Both groups of tumors are clearly different with regard to conventional light microscopy, immunohistochemistry, molecular pathology and clinical features.
  • Only type I carcinomas are associated with hyperestrogenism.
  • The group of type I carcinomas consists of endometrioid carcinoma and its variants, and mucinous carcinoma.
  • The prototypes of type II carcinomas are serous and clear cell carcinoma.
  • Not all carcinomas, however, can be assigned to one of the two groups, because there are hybrid tumors and mixed carcinomas, e.g. endometrioid carcinoma with a serous component.
  • Of utmost importance is the detection of a serous component, because serous carcinoma leads to early tumor spread with the necessity of radical surgery, chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124 Suppl:S42-51 [16468417.001]
  • [Cites] Pathology. 2007 Feb;39(1):134-8 [17365829.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):145-84 [11981113.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):279-289 [11494005.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):569-75 [8179072.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):769-74 [7793474.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53 [15086736.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):328-33 [17581420.001]
  • [Cites] Pathol Res Pract. 1992 Oct;188(7):856-9 [1448376.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):157-66 [15644772.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1740-7 [8859187.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):463-9 [14675663.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):37-42 [19116629.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19495762.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


98. Oudidi A, El-Alami MN, Boulaich M, Jazouli N, Kzadri M: [Primary sub-mandibular gland tumours: experience based on 68 cases]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):187-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sub-mandibular gland tumours: experience based on 68 cases].
  • [Transliterated title] Les tumeurs primitives de la glande sous-maxillaire: à propos de 68 cas.
  • Sub-mandibulary gland tumours are less common than tumours of the parotid and pose many clinical and therapeutic challengers.
  • PATIENTS AND METHODS: Retrospective studies of sub-mandibular gland tumours presenting to our department between 1986 and 2000.
  • RESULTS: 68 cases were reviewed comprising 37 benign and 31 malignant tumours (15 females and 33 males).
  • Average age of patient was 46 years and all presented with a sub-mandibular swelling.
  • CAT Scans were performedd to assess tumour extent / invasion.
  • Definitive diagnosis was by complete excision and pathological examination.
  • Pleomorphic adenoma (n= 32) were the most frequent benign tumours.
  • Treatment was by total surgical excision of the submandibular gland for the begnin tumours.
  • Radiotherapy was performed in 24 cases and chemotherapy in 10 cases.
  • CONCLUSION: Malignity in sub-mandibular gland tumours is more frequent than in the parotid gland.
  • [MeSH-major] Submandibular Gland Neoplasms / classification. Submandibular Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007195.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


99. Mandoky L, Geczi L, Bodrogi I, Toth J, Bak M: Expression of HER-2/neu in testicular tumors. Anticancer Res; 2003 Jul-Aug;23(4):3447-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HER-2/neu in testicular tumors.
  • BACKGROUND: Although the overexpression of the Epidermal Growth Factor Receptor 2 (EGFR-2, HER-2/neu, c-erbB-2) in malignancies might predict chemoresistance and poor prognosis, its clinical relevance has not been widely studied and determined in testicular tumors.
  • PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized immunohistochemical method (HercepTest Kit).
  • RESULTS: Seven (25%) out of 28 non-seminomatous germ cell tumors showed HER-2/neu positivity.
  • The teratomatous components of mixed GCTs showed HER-2/neu overexpression in 5 cases.
  • Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu.
  • Among the HER-2/neu-positive cases, 3 patients are in complete remission, 3 patients are in partial remission and one patient died after primary chemotherapy.
  • CONCLUSION: Twenty-five percent of the non-seminomatous germ cell tumors which contain teratomatous components overexpress HER-2/neu protein.
  • Further molecular investigations and clinicopathological studies are necessary to determine the correlation between HER-2/neu overexpression and clinical resistance of testicular tumors.
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / drug therapy. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Humans. Immunohistochemistry. Male. Neoplasm Staging. Seminoma / drug therapy. Seminoma / metabolism. Seminoma / pathology. Teratoma / drug therapy. Teratoma / metabolism. Teratoma / pathology. Treatment Outcome


100. Hafezi-Bakhtiari S, Morava-Protzner I, Burnell MJ, Reardon E, Colgan TJ: Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. J Obstet Gynaecol Can; 2010 Jul;32(7):698-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment.
  • Nevertheless, recognition of this mixed tumour is important for administration of appropriate chemotherapy.
  • CASE: A 65-year-old woman underwent resection of an ovarian mass after presenting with a pelvic mass and breast tenderness.
  • On pathologic examination the mass showed a choriocarcinoma in association with a serous carcinoma.
  • This pathologic diagnosis led to a specific chemotherapy regimen with cisplatin, etoposide, and bleomycin, suitable for both types of malignancy.
  • CONCLUSION: Both gynaecologists and pathologists should be aware that the histopathologic classification of ovarian epithelial carcinoma and its variants, such as this one, may have an increasing role in the management of this disease.

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707961.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down






Advertisement